Marshall University Marshall Digital Scholar

Theses, Dissertations and Capstones

2008

Effects of aging and gender on regulators of muscle adaptation in F344/BN rat model

Satyanarayana Paturi

Follow this and additional works at: http://mds.marshall.edu/etd Part of the <u>Biology Commons</u>, and the <u>Musculoskeletal</u>, <u>Neural</u>, and <u>Ocular Physiology</u> <u>Commons</u>

Recommended Citation

Paturi, Satyanarayana, "Effects of aging and gender on regulators of muscle adaptation in F344/BN rat model" (2008). *Theses, Dissertations and Capstones.* Paper 779.

This Thesis is brought to you for free and open access by Marshall Digital Scholar. It has been accepted for inclusion in Theses, Dissertations and Capstones by an authorized administrator of Marshall Digital Scholar. For more information, please contact chapsilon_result.

Effects of aging and gender on regulators of muscle adaptation in F344/BN rat model

By

Satyanarayana Paturi A thesis submitted to the

Graduate faculty of the Department of Biology

At

Marshall University

In partial fulfillment of the requirements for the degree

Of

Master of Science

Committee:

Dr. Eric Blough (Thesis adviser)	
Dr. David Mallory (Committee member)	
Dr. Simon Collier (Committee member)	

Fall 2008 Marshall University West Virginia

ABSTRACT

Sarcopenia is the loss of muscle mass and strength that occurs with aging. Here we examine the effects of aging and gender on the regulation of molecules believed to regulate muscle growth and adaptation in the F344/BN rat. In male animals, soleus and EDL muscle/body weight ratio declined continuously with aging while muscle atrophy in female animals plateaued at 26-months and remained constant thereafter. Aging increased the phosphorylation of protein kinase-B (Akt) and the mammalian target of rapamycin (mTOR) in the female but not male soleus muscle. This finding was associated with the attenuation of muscle atrophy observed in female animals. Male and female soleus muscles exhibited higher p70S6k phosphorylation with aging. Irrespective of muscle type or gender, aging was associated with increased calcineurin expression. Taken together, these data suggest that indices of protein synthesis and muscle adaptation are regulated differently with aging in different muscle types and gender.

(Keywords: Aging, sarcopenia, F344/BN, muscle, gender, soleus, EDL, diaphragm)

ACKNOWLEDGEMENTS

- Dr. Eric Blough
- Dr. Simon Collier and Dr. David Mallory
- Molecular physiology lab
- National Institute of Aging Grant to EB, Marshall University and NSF EPSCoR grant to Marshall University

Table of Contents

ABSTRACT	ii
ACKNOWLEDGEMENTS	iii
LIST OF SYMBOLS	v
LIST OF FIGURES	vi
CHAPTER-I	
INTRODUCTION	1
HYPOTHESIS/PURPOSE OF STUDY	4
SIGNIFICANCE OF STUDY:	5
CHAPTER-II	6
CHAPTER-III	17
INTRODUCTION	19
MATERIAL AND METHODS	21
Animals	21
Materials	22
Tissue isolation	22
Western blotting	22
Data Analysis	24
RESULTS	25
DISCUSSION	28
Effects of aging on indicators of muscle adaptation	28
Aging increases the muscle content of calcineurin	
ACKNOWLEDGEMENTS	
CHAPTER IV	
CONCLUSIONS	
FUTURE DIRECTIONS	50
APPENDIX	52
REFERENCES	

LIST OF SYMBOLS

AAALAC	Association for assessment and accreditation of	
	laboratory animal care	
CSA	Cross sectional area	
EDL	Extensor digitorum longus	
elF-4	Eukaryotic initiation factor - 4	
F344/BN	Fisher 344 Brown Norway hybrid	
GSK-3ß	Glycogen synthase kinase 3 beta	
IGF-1	Insulin like growth factor-1	
IOD	Integrated optical densities	
KRB	Krebs-Ringers Buffer solution	
MAPK	Mitogen activated protein kinase	
mTOR	Mammalian target of rapamycin	
NF-AT	Nuclear factor activating T cells	
p70S6K	p70 ribosomal s6 kinase	
ROS	Reactive oxygen species	
4E-BP1	Eukaryotic initiation factor 4E binding protein-1	

LIST OF FIGURES

Figure 1	
Figure 2	
Figure 3	
Figure 4	
Figure 6	
Figure 7	
Figure 8	47
•	

CHAPTER-I

INTRODUCTION

Sarcopenia is the loss of muscle mass that occurs as a result of the aging process. The number of aged (>60 years) increased from 31.2 million people in 1990 to 35.0 million in 2000 in the United States (WHO Brasilia declaration on healthy aging, 1996). It has been estimated that the direct healthcare costs of sarcopenia were \$18 billon in the United States in 2000 [1] with this number expected to rise as the number of aged increase. Sarcopenia is a consequence of normal aging that is characterized by decreased muscle strength, reduced performance and diminished quality of life [2, 3], Indeed, by the seventh and eighth decade of life, maximal voluntary contractile strength is decreased, on average, by 20–40% for both men and women. The etiology of sarcopenia includes physical inactivity, motor-unit remodeling, decreased protein synthesis, increased cytokine activity, oxidative stress, and decreased hormone levels[4]. How gender differences may affect the cause or progression of sarcopenia is not well understood [5].

Rat models and substrains exhibit different life expectancies [6] and biological characteristics [7]. Probability of survival curves generated by the National Institute of Aging (NIA) were employed to identify F1 generation hybrid of Fischer 344/NNiaHSd X Brown Norway/BiNia (F344/BN), male and female rats ages so as to correspond roughly to humans in their third, seventh, and eighth decade of life, respectively [8]. This latter time point was chosen because the World Health Organization defines this age

group as "elderly", a time where muscle atrophy and dysfunction are present and accelerating in humans [9]. The relatively new F344/BN hybrid model appears to be more resistant to diseases associated with aging [10] than the Fischer 344 (F344) rat strain. Average survival age is higher in the F344/N X BN than the F344, suggesting perhaps that they are a better model of age-related muscle loss since they appear to survive long enough to develop sarcopenia [10]. How aging affects skeletal muscle in the aging F344/BN is not well understood. Indeed, to our knowledge, there are no studies that have compared aging male and female F344/BN rats together within the same study.

Aging in the rodents is accompanied by a progressive loss of skeletal muscle fibers. The muscle twitch also becomes slower, probably as a result of fiber-type conversion from fast-twitch glycolytic to slow-twitch oxidative fibers [11]. Recent data has demonstrated that fast twitch and slow twitch muscles in male animals respond differently during aging [11, 12]. Whether similar differences between muscle types are observed in the aging female F344/BN rat has not been investigated.

Although age-associated decreases in strength per unit muscle mass, or muscle quality, may play a role, the majority of strength loss can be accounted for by decreased muscle mass [13]. It is thought that the ability of skeletal muscle to adapt to an increased contractile stimulus diminishes with aging [14]. The mechanism(s) responsible for this decreased adaptive potential are not clear. Studies investigating striated muscle hypertrophy have established that the p70 ribosomal protein S6 kinase (p70S6k) plays a critical role in regulating protein synthesis and muscle adaptation following an exercise stimulus [15-17]. In addition to p70S6k, protein kinase B (Akt),

glycogen synthase kinase-3 beta(GSK - 3β), the mammalian target of rapamycin (mTOR) and calcineurin (CnA), have also been identified as key signaling molecules involved in the regulation of muscle adaptation to increased contractile loading [18]. How the regulation of these molecules is altered with aging or with genders is not well understood.

HYPOTHESIS/PURPOSE OF STUDY

Our long term goal is to identify the cellular and molecular mechanisms of agerelated skeletal muscle loss. The present study was designed to determine whether aging alters the regulation of proteins thought to be involved in regulating muscle adaptation. Here we examine the effects of aging and gender on the expression and phosphorylation of Akt, mTOR, p70S6k, and calcineurin in the fast-twitch extensor digitorum longus (EDL), the slow-twitch soleus and the continuously active diaphragm. We hypothesized that aging will alter the concentration of signal transduction proteins in EDL, soleus and diaphragm differently and that the regulation of these molecules may differ across genders.

- **Specific Aim:** To determine how aging effects the regulation of p70S6k, Akt, mTOR and calcineurin in the male and female F344/BN EDL, soleus and diaphragm muscles.
- **Hypothesis:** Aging will alter the regulation of p70S6k, Akt, mTOR and calcineurin differently in male and female F344/BN EDL, soleus, and diaphragm muscles.

SIGNIFICANCE OF STUDY:

Sarcopenia is associated with increased health care costs and negatively impacts quality of life for many of the United States aging population. A greater understanding of the factors that cause and contribute to the progression of sarcopenia is needed. Further studies on the mechanisms leading to sarcopenia could provide the basis for prevention and the establishment of therapeutic methods that will contribute to an increase in the standard of living among elderly people [19]. This study will determine how aging alters the regulation of proteins thought to govern muscle adaptation. The identification of age-related changes in the regulation of these proteins could lead to a greater understanding of the mechanisms leading to sarcopenia and could provide the basis for the establishment of therapeutic interventions that could be used to target sarcopenia.

CHAPTER-II

REVIEW OF LITERATURE

INTRODUCTION

A review of the pertinent literature concerning the present study will be presented in the following chapter. The following areas will be addressed: 1) Age associated alterations in skeletal muscle, 2) Regulators of muscle plasticity and protein synthesis, and 3) Effects of gender on age-related changes in muscle mass and quality.

Age associated alterations in skeletal muscle

Isometric and dynamic strength increases up to the third decade, remains almost constant to the fifth decade, and then decreases with increasing age [20]. The loss of muscle mass and strength with aging, also referred to as sarcopenia, is highly prevalent and predicts several adverse outcomes, including disability, institutionalization and mortality. Although the exact mechanisms underlying sarcopenia are unknown, accumulating evidence suggests that an age-related acceleration of myocyte loss via apoptosis might represent a key mechanism driving the onset and progression of muscle loss [21]. A number of physiological factors have been suggested to be involved in sarcopenia, including an age-related reduction of growth hormone [22], thyroxine [23], and, in women and men, estrogen and testosterone [24], respectively. A number of mechanisms proposed include alterations in motor unit organization [25-28], contraction-induced injuries [29, 30], deficient satellite cell recruitment [31], increases in

free radicals and oxidative stress [32, 33], and age-related accumulation of mitochondrial abnormalities. Young *et al.*, (1984, 1985), used ultrasonography and found 25-35% reductions in the cross sectional area of the quadriceps muscle in men and women over the age of 65 years when compared to young [34, 35]. The computed tomography scanning technique, performed by several researchers, has shown similar age-related reductions in cross sectional area of the psoas major and sacrospinalis muscles,[36] the quadriceps muscle [37], the brachial biceps and triceps muscles[38, 39] and the plantar flexors [38, 39] of men over the age of 65.

A great deal of research on aging has been performed on the aged rats because of the difficulties associated with aging studies in humans such as ethical, cross sectional design and inability to control life time activity pattern of the subjects. As with human beings, aging in animals also appears to affect muscle function. In rodents, several investigators have noted a similar, preferential reduction in type II fiber cross sectional area (CSA) and little or no decline in type I fiber CSA [40, 41]. Taken together, these data suggest that age-associated changes in fiber cross sectional area, muscle mass, may vary across different muscle fiber types and muscles depending on whether the muscle is used for weight bearing or non-weight bearing activity [42].

Skeletal muscle exhibits a great deal of plasticity, which is specific to the stimulus it receives [43, 44]. Muscle plasticity or the ability of muscle to adapt to an altered contractile stimulus decreases with aging in both humans and animals [14, 45-49]. Hypertrophy of muscle cells in response to increased functional demand is a well established phenomenon. It has been shown that resistance training in humans leads to muscle hypertrophy which is mainly the result of an enhanced cross-sectional area of

individual muscle fibers [23, 50, 51]. Similar adaptations have been observed in animals after ablation or denervation of synergistic muscles [50, 52]. The mechanisms underlying age-associated decreases in muscle plasticity are unknown. Faulkner *et al.*, 2007 concluded that, for both humans and rats, the timing and magnitude of the loss of motor units is similar to that for muscle fibers which suggests that the mechanism responsible for the loss of fibers and for the loss of whole motor units is the same. It is thought that the degree of atrophy of the fibers that remain is largely dependent on the habitual level of physical activity of the individual [53].

Summary:

The age associated deterioration in size, mass, and function of skeletal muscle was observed in both human and animal skeletal muscle and can be or at least partly be reversed by resistance training. These age associated changes may be due to changes in hormonal activity, muscle type (weight bearing or non weight bearing), or due to increased oxidative stress and several others, but the exact molecular mechanisms underlying the sarcopenia is still unknown.

Regulators of muscle plasticity and protein synthesis

A decrease in the production of anabolic hormones such as testosterone, growth hormone and insulin-like growth factor-1(IGF-1) impairs the capacity of skeletal muscle to incorporate amino acids and synthesize proteins. An increase in the release of catabolic agents, specifically interleukin-6, amplifies the rate of muscle wasting among the elderly [54]. IGF-1 belongs to the insulin family of peptides and acts as a growth factor in any tissues and tumors. Locally acting IGF-1 enhances muscle growth and differentiation, prevents age related muscle atrophy, and potentiates regeneration after injury [55, 56]. IGF-1 also increases skeletal muscle anabolic processes and attenuates the ubiquitin – proteasome pathway and the formation of oxidative products. Similarly, IGF-1 decreases oxidative damage in the myocardium with aging [57]. Entela et al., in 2001, examined mitochondrial abnormalities in muscles undergoing sarcopenia and concluded that different muscles accumulate different levels of electron transport system abnormalities during normal aging and also that these electron transport system abnormalities contribute to senescent muscle atrophy [58]. The exact role of the mitochondria in muscle sarcopenia is not well understood.


Tumor necrosis factor-alpha (TNF- α) is elevated in the serum as a result of aging and it promotes pro-apoptotic signaling upon binding to the type I TNF receptor [59]. It is not known if activation of this apoptotic pathway contributes to the well documented age-associated decline in muscle mass. Skeletal muscles containing type II fibers are more susceptible to muscle mass losses via the extrinsic apoptotic pathway [60]. There is an overall increase in calpain activities associated with muscle aging,

suggesting that the calcium-dependent proteolytic system is indeed involved in sarcopenia [61]. Calcineurin (CnA), a calcium-sensitive phosphatase, plays a critical role in transduction of calcium(Ca²⁺) signals in different types of cells [62]. The main substrate of calcineurin is the nuclear factor of activated T cells (NFAT), a family of transcription factors (NFATC1–C4). During periods of sustained elevations of calcium, calcineurin dephosphorylates NFATC1–C4, allowing NFAT to translocate to the nucleus. A Ca²⁺-dependent CnA signaling pathway has been implicated both in the hypertrophic response and in the neurally dependent transition of skeletal muscle from fast-twitch to the slow-twitch phenotype [63, 64]. How CnA is regulated with aging in skeletal muscle has not been fully elucidated.

Human sarcopenia may be linked to a reduction in the activity or sensitivity of anabolic signaling proteins such as growth hormone receptor (GHR), IGF-1, and protein kinase B (Akt). In addition, TNF- α , suppressor of cytokine signaling-3 (SOCS-3), and myostatin are other potential candidates that may be involved in regulating age-associated muscle loss [65]. A lack of myostatin appears to reduce age-related sarcopenia and loss of muscle regenerative capacity [66]. Akt plays a number of roles that may be important in sarcopenia including suppression of apoptosis and the modulation of muscle-specific protein degradation via the inhibition of the expression of the ubiquitin E3 ligases atrogin-1 and muscle ring factor-1 (MuRF-1). Akt activity also promotes protein translation via the inhibition of glycogen synthase kinase-3 β and the activation of mammalian target of rapamycin (mTOR). The activation of Akt is known to be sensitive to insulin and IGF-I levels [67]. The phosphatidyl inositol 3-kinase(PI3K) signaling substrate mTOR has been implicated in skeletal muscle hypertrophy during

overload [68]. After an acute bout of contractile activity and during chronic periods of overload, phosphorylation of mTOR and its downstream target 70-kDa ribosomal protein S6 kinase (p70S6K) are increased [68-71], and the degree of p70S6K phosphorylation after a single bout of contractile activity is strongly associated with increase in muscle weight. Correspondingly, pharmacological inhibition of mTOR prevents overload-induced hypertrophy in both type I and type II fibers [68]. Bodine *et al.*, in 2001, concluded that activation of the Akt/mTOR pathway and its downstream targets, p70S6K and PHAS-1/4E-BP1, is requisitely involved in regulating skeletal muscle fiber size, and that activation of the Akt/mTOR pathway can oppose muscle atrophy induced by disuse [68]. How aging may affect the ability of skeletal muscle to regulate Akt \rightarrow mTOR \rightarrow p70S6k signaling is not well understood.

Figure 1



Schematic representation of molecules thought to be involved in Akt-mTOR pathway

Although extracellular regulated kinase 1/2 (ERK1/2) activity does not appear to be sufficient for myogenesis *in vitro* or for muscle hypertrophy *in vivo* [72], ERK1/2 signaling is required for proliferation of satellite cells and may play a permissive role in the network of signals required for regeneration and hypertrophy of skeletal muscle. Emerging evidence suggests that nuclear factor-kappa B (NF-kappa B) is one of the most important signaling pathways linked to the loss of skeletal muscle mass in various physiological and patho-physiological conditions. Activation of NF-kappa B in skeletal muscle leads to degradation of specific muscle proteins, induces inflammation and fibrosis, and blocks the regeneration of myofibers after injury / atrophy [73]. How aging may alter the regulation of ERK1/2 and NF-kappa B in skeletal muscle has not been established.

<u>Summary</u>

The protein content in a skeletal muscle is dependent on the rate of protein synthesis and the rate of protein degradation. The anabolic hormones like growth hormone, insulin, testosterone in males, and estrogen in females initiates protein synthesis *via* several signaling pathways. Akt activity promotes protein translation via the inhibition of glycogen synthase kinase-3 β and the activation of mammalian target of rapamycin (mTOR) and it's down stream protein, s6 ribosomal protein kinase (p70S6k). An increase in the release of catabolic agents like interleukin-6, TNF- α and activation of molecules like nuclear factor-kappa B(Nf-KB), B-cell CLL/lymphoma 3(BCL3) amplifies the rate of protein degradation in skeletal muscle among the elderly. How skeletal

muscle is able regulate all these anabolic and catabolic molecules with aging is not well understood.

Effects of gender on age-related changes in muscle mass and quality

In the developed world, most women live one-third of their lives in a state of profound estrogenic deprivation [74]. In addition, with advancing age of women there is a decrease in the serum levels of testosterone and androgens [75]. Moreover, elderly males have altered local levels of bioactive estrogens, secondary to reduced secretion of adrenal sex-steroid precursors to estrogen by aromatization [76]. Age-related strength losses are secondary to decline in skeletal muscle mass in men and women. While women may experience earlier strength losses than men, overall, age associated decreases in strength are similar. Although men may experience greater losses of total muscle mass, recent evidence points toward greater declines in muscle guality in older women [77]. Men are stronger than women at all ages [78] and in both sexes the average values for maximum voluntary strength of the dorsi flexors and plantar flexors begin to decline in the 6th decade [78]. Body mass index (BMI) is a strong predictor of skeletal muscle mass in women and men. The relative rate of skeletal muscle loss in men substantially exceeds the relative rate of bone mineral loss. In women, the relative losses of skeletal muscle and bone proceed at similar rates [79]. Aging men and women would therefore be anticipated to develop very different musculoskeletal relationships in old age. Falls, weakness, frailty, and ultimately fractures can potentially arise from changes in bone composition and quality, a loss of supporting and protective skeletal muscle, or a combination of the two [13, 79]. Several studies have shown differences in the prevalence of sarcopenia between men and women, with men being more susceptible [80-82], again suggesting that hormones may play a role in age-related muscle loss. Sex-related differences exist at the whole muscle and single fiber levels

with regarding to the strength and fiber cross-sectional area [83]. There is epidemiological data suggesting that there is a relationship with reduced testosterone levels and the decline in muscle mass, strength and functional status [84-86]. Testosterone replacement has resulted in increased muscle mass and strength in hypogonadal populations, elderly men and increased strength and protein synthesis in elderly women [87].

Age-related sarcopenia is largely confined to type II muscle fibers when compared to type I muscle fibers [88]. Rice KM and Blough ER, in 2006, worked on sarcopenia related apoptosis in different muscle fiber types and concluded that the apoptotic regulatory events differ between fiber types in the aging male F344/BN rats and that mitochondrial-dependent apoptosis pathways may not play a primary role in the loss of muscle nuclei with aging [89]. Whether similar findings are observed in the aging female F344/BN rats is not known.

Satellite cells are small mononuclear progenitor cells with virtually no cytoplasm found in mature muscle. They are found sandwiched between the basement membrane and sarcolemma (cell membrane) of individual muscle fibers, and can be difficult to distinguish from the sub-sarcolemmal nuclei of the fibers. This cell type was discovered in 1961 by Mauro in muscles of anuran amphibians and given the term satellite cells. Although satellite cells are found in all muscle fibers their distribution is imbalanced. Increased numbers of satellite cells are found within muscles composed of type I, slow oxidative fibers such as the soleus compared with muscles composed of type II, fast glycolytic fiber types such as EDL [90]. How aging affects the regulation of muscle satellite cells is not well understood.

Summary:

Sarcopenia is observed in both males and females but the molecular mechanism underlying the incidence of sarcopenia is not well understood. The sarcopenia involves more of the type II, fast glycolytic fibers than the type I, slow oxidative fibers in aging males but whether similar findings are observed in the aging females is not known. The molecular signaling mechanisms occurring in different muscle types and genders should be looked at to investigate the differences in signaling with gender, age, and fiber type.

CHAPTER-III

Effects of aging and gender on regulators of muscle adaptation in F344/BN rat model

Satyanarayana Paturi^{1, 2} and Eric R Blough^{1, 2}

- ^{1.} Department of Biological Sciences, Marshall University
- ^{2.} Cell Differentiation and Development Center, Marshall University

Author for correspondence:

Eric Blough, Ph.D., Laboratory of Molecular Physiology, Department of Biological Sciences, Room # 241N, 217, 218 BBSC Building, 1700, 3rd avenue, Marshall University, Huntington, WV 25755-1090. E-mail: <u>blough@marshall.edu</u>

ABSTRACT

Sarcopenia is the loss of muscle mass and strength that occurs with aging that if allowed to proceed unchecked can lead to disability. Here we compare the total content and phosphorylation levels of several molecules believed to regulate muscle growth and adaptation in the slow twitch muscle-soleus, the fast twitch muscle-extensor digitorum longus (EDL), and the continuously active diaphragm muscles of 6-(adult), 30-(aged), and 36-month(very aged) male and 6-(adult), 26-(aged), and 30-month(very aged) female Fischer 344XBrown Norway rats. In male animals, soleus and EDL muscle/ body weight ratio was lower in the 30-month (6- vs. 30-month soleus: 20% (P<0.05); 6- vs. 30-month EDL: 25.58%, (P<0.05)) animals and decreased further at 36-months (30- vs. 36-month soleus: 18.75%, (P<0.05) ; 30- vs. 36-month: EDL 15.63% (P<0.05)). Conversely, muscle atrophy in the aging female animals plateaued at 26-months and remained constant thereafter (6- vs. 26-and 30-month soleus: 25%(P<0.05) and 25%); 6- vs. 26- and 30-month EDL: 23.52%(P<0.05) and 27.45%). Aging increased the phosphorylation (activation) of protein kinase B (Akt) and the mammalian target of rapamycin (mTOR) in the female soleus. Both the male and female soleus exhibited higher p70S6k phosphorylation with aging while the aged EDL and diaphragm muscles failed to exhibit increased phosphorylation of Akt, mTOR or p70S6k with aging. Irrespective of muscle type, aging in both the genders was associated with increased calcineurin expression. Taken together, these data suggest that indices of protein synthesis and muscle adaptation are regulated differently with aging in different muscle types and gender.

INTRODUCTION

Sarcopenia is the loss of muscle mass that occurs as a result of the aging process. It has been estimated that the direct healthcare costs of sarcopenia are in excess of \$18 billon in the United States [1] and this number is expected to rise as the number of aged increase. Age-related atrophy is thought to be a consequence of normal aging and it is characterized by decreased muscle strength, reduced performance and diminished quality of life [2, 3]. Indeed, by the seventh and eighth decade of life, maximal voluntary contractile strength is decreased, on average, by 20-40% for both men and women. The etiology of sarcopenia is not fully understood but likely includes changes in physical inactivity, motor-unit remodeling, decreased protein synthesis, increased cytokine activity, oxidative stress, and decreased hormone levels [4]. How gender differences may affect the cause or progression of sarcopenia is not well understood [5]. Similarly, recent data has also demonstrated that fast twitch and slow twitch muscles in male animals respond differently during aging [11, 12]. Whether similar differences between muscle types are observed in the aging female rats has not, to our knowledge, been investigated.

The molecular mechanism(s) underlying age-associated muscle loss remain to be elucidated. Studies investigating striated muscle hypertrophy have established that the p70 ribosomal protein S6 kinase (p70S6k) plays a critical role in regulating protein synthesis and muscle adaptation following an exercise stimulus [15-17]. In addition to p70S6k, several other molecules including protein kinase B (Akt), mammalian target of rapamycin (mTOR) and calcineurin (CnA) have also been identified as key signaling molecules involved in the regulation of muscle adaptation to increased contractile

loading [18]. How the regulation of these molecules is altered with aging or gender is not well understood. The purpose of this investigation was to examine the regulation of Akt, mTOR, p70S6k and calcineurin with aging in male and female Fischer 344/NNiaHSd X Brown Norway/BiNia (F344/BN) rats. Given the fact that muscle mass and adaptation decrease with increasing age, we hypothesized that the regulation of molecules involved in governing this process may also be altered with aging. Using probability of survival curves generated by the National Institute of Aging (NIA) we selected differently aged male and female F344/BN rats corresponding roughly to humans in their third, seventh, and eighth decades of life [8]. This latter time point was chosen because the World Health Organization defines this age group as "elderly", a time where muscle atrophy and dysfunction are present and accelerating in humans [9]. Our findings suggest that indices of muscle adaptation are regulated differently with aging in different muscle types and gender.

MATERIAL AND METHODS

Animals

All procedures were performed in accordance with the Guide for the Care and Use of Laboratory Animals as approved by the Council of the American Physiological Society and the Animal Use Review Board of The Marshall University. All procedures were conducted in strict accordance with Public Health Service animal welfare policy. Adult (6 months), aged (30 months) and very aged (36 months) male and Adult (6 months), aged (26 months) and very aged (30 months) female F1 Fischer 344/NNiaHSd X Brown Norway/BiNia rats were obtained from the National Institute on Aging. Rats were barrier housed two per cage in an AAALAC approved vivarium. Housing conditions consisted of a 12 Hour: 12 Hour dark-light cycle and temperature was maintained at 22 ± 2 °C. Animals were provided food and water ad libitum. Rats were allowed to recover from shipment for at least two weeks before experimentation began, and during this time the animals were carefully observed and weighed weekly. None of the older animals exhibited signs of failure to thrive, such as precipitous weight loss, disinterest in the environment, or unexpected gait alterations. Systolic blood pressure was determined with the animal un-anaesthetized using a programmed electro sphygmomanometer with pneumatic tail cuff (Narco - Biosystems, Houston, TX). Animals were acclimatized to the procedure for a minimum of 3 days prior to obtaining blood pressure.

Materials

Total and phosphorylated forms of AKT (catalog # 9272, 9271, 9275), m-TOR (catalog # 2972, 2971), P70S6K (Catalog # 9202, 9204, 9234) and mouse IgG and rabbit IgG antibodies were purchased from Cell Signaling Technology (Beverly, MA). Calcineurin (catalog # C1956) antibody was purchased from Sigma-Aldrich (St. Louis, MO). Precast 10% SDS-PAGE gels were procured from Cambrex Biosciences (Baltimore, MD), and enhanced chemiluminiscence (ECL) western blot detection reagent was from Amersham Biosciences (Piscataway, NJ). Restore western blot stripping buffer was obtained from Pierce (Rockford, IL) and 3T3 cell lysates were from Santa Cruz Biotechnology (Santa Cruz, CA). All other chemicals were purchased from Sigma-Aldrich (St. Louis, MO).

Tissue isolation

Animals were anesthetized with a ketamine-xylazine (4:1) cocktail (50 mg/kg intra peritoneal injection) and supplemented as necessary for reflexive response. Soleus, EDL, and diaphragm muscles were quickly removed, blotted dry, weighed, and immediately frozen in liquid nitrogen. Tissues were stored at -80° C until use.

Western blotting

Soleus, EDL, and diaphragm muscles were homogenized on ice, 2 times for 30 seconds in T-PER (2mL/100mg tissue weight) supplemented with 1mM PMSF, 1mM

Na₃VO₄, and 1mM NaF. After homogenization and centrifugation (9000 X g X 60 min. at 4°C), the supernatant was separated from the pellet and stored in aliquots at -80°C until use. Protein concentrations of the supernatant were determined in triplicate using bovine serum albumin (BSA) as a standard and the Bradford method (Pierce, Rockford, IL). Samples were diluted to a concentration of 2.5mg/ml in SDS-loading buffer and after boiling for 5 minutes, 50 µg of total protein for each age or time point were separated on 10% SDS-PAGE precast gels. Western blot transfer of protein onto nitrocellulose membranes was performed using standard conditions. To verify transfer of proteins and equal loading of lanes the membranes were stained with Ponceau S. For immune detection, membranes were blocked in 5% Milk in TBS-T for 1 hour at room temperature and then incubated with the appropriate primary antibody overnight at 4°C. After washing in TBS-T, the membranes were exposed to horseradish peroxidaselabeled IgG secondary antibody for 1 hour at room temperature. Protein bands were visualized with ECL (Amersham Biosciences). Exposure time was adjusted to keep the integrated optical densities (IODs) within a linear and non-saturated range, and band signal intensity was quantified by densitometry using a flatbed scanner (Epson Perfection 3200 PHOTO) and Imaging software (Alpha Ease FC). Molecular weight markers (Cell Signaling) were used as molecular mass standards and NIH 3T3 cell lysates were included as positive controls. To allow direct comparisons between expression levels of different signaling molecules, immunoblots were stripped with Restore western blot stripping buffer as detailed by the manufacturer (Pierce, Rockford, IL) and re-probed. After verifying the absence of residual HRP activity on the membrane by reaction with the ECL reagent, membranes were washed and re-probed.

Data Analysis

Results are presented as mean \pm SEM. Multiple group comparisons were performed by two-way ANOVA followed by post-hoc testing where appropriate. For all comparisons, the alpha level was set at P < 0.05

RESULTS

Body mass, muscle mass and morphology

In male animals, soleus and EDL muscle / body weight ratio was lower in the 30month (6-month soleus vs. 30-month: 20%, (P<0.05); 6-month EDL vs. 30-month: 25.58% (P<0.05)) animals and decreased further at 36-months (30-month soleus vs. 36-month soleus: 18.8%, (P<0.05) ;30-month EDL vs. 36-month: EDL 15.6% (P<0.05)) (Figure 1). Conversely, muscle atrophy in the aging female animals plateaued at 26months and remained constant thereafter (6 month soleus vs. 26-and 30-month: 25% (P<0.05) and 25%); 6 month EDL vs. 26- and 30-month: 23.5% (P<0.05) and 27.5%).

<u>Aging effects on AKT-mTOR-p70S6K pathway related protein expression and</u> <u>phosphorylation</u>

To investigate whether aging affected the total and phosphorylated amounts of AKT, mTOR, and p70S6k expression in the skeletal muscle, we performed protein gel electrophoresis and immunoblotting using antibodies which recognize both the unphosphorylated and phosphorylated forms of these molecules. Immunoreactive bands of ~60kDa, ~289kDa, and ~70kDa, corresponded to the predicted molecular mass of the AKT, mTOR, and p70S6k respectively.

<u>Soleus</u>

Aging did not alter the amount of p-Akt (Ser 308) or p-Akt (Ser 473) in the male soleus. Compared to 6-month animals the amount of p-mTOR was 27.1% lower in the 36-month soleus (Fig 4A). Relative to 6-month animals, p-p70S6k (Ser 389) was 86% higher in 36-month old animals while calcineurin levels were 118.1% and 279.9% higher in the soleus muscles of 30- and 36-month animals (Figs. 5A and 6A). Opposite of what we found in the male animals, the amounts of p-Akt (Ser 308), p-Akt (Ser 473) and p-p70S6k (ser 389) were 141.1%, 182.1%, and 96 % higher in the soleus of 30-month female animals. Compared to 6-month animals, the amount of p-mTOR was 53.9% and 104.9% higher in 26- and 30-month female animals (Fig. 4A). Calcineurin levels were 17.4% and 63.3% higher in the soleus muscles of 26- and 30-month animals (Fig 6A).

<u>EDL</u>

Compared to the 6-month animals the amount of p-Akt (ser 473) was 29% higher in the EDL muscles of 36-month male and the amount of p-mTOR and p-p70S6k (ser389) were 27.1% and 79.7% lower in the 36-month male EDL(Fig 3B, 4B and 5B). Relative to the 6-month animals, the calcineurin levels were 183.7% and 259.3% higher in 30- and 36-month animals (Fig 6B). In female rats, aging did not alter the levels of p-Akt (Ser 473), p-mTOR, and p-p70S6k (Ser 389). Relative to the 6-month animals, the p-Akt (Ser 308) levels were 24.5% lower in 30-month (Fig 3B) and calcineurin levels were 69.2% and 116.1% higher in 26- and 30-month animals(Fig 6B).

Diaphragm

Aging did not alter the levels of p-Akt (Ser 308), p-Akt (Ser 473), and p-mTOR in the diaphragm of both male and female animals. Compared to the 6-month male animals the amount of p-p70S6k (Ser 389) was 42.6% higher in 36-month and did not change in female animals (Fig 5C). Relative to the 6-month male animals the amount of calcineurin was 76.7% and 351.9% higher in 30- and 36-month animals(Fig 6C). In female animals the calcineurin levels were 34.1% and 25.3% higher in 26- and 30month animals (Fig 6C).

DISCUSSION

The intent of this study was to examine the effects of age on the intramuscular concentration of proteins thought to regulate protein synthesis and muscle plasticity in the fast-twitch EDL, the slow-twitch soleus, and diaphragm. Probability of survival curves generated by the NIA were employed to identify animal ages so as to correspond roughly to humans in their third, seventh, and eighth decade of life, respectively. The major finding of the present study is that the extent and potential mechanisms of age-related muscle atrophy may differ between muscles and with gender. Whether the changes we observe here in aging rats are also applicable to aging humans will require further studies.

Effects of aging on indicators of muscle adaptation

Similar to previous reports examining the effects of age on muscle mass in aging F344/BN male rats[10, 89] we found skeletal muscle mass continued to decrease with increasing age (Fig 1). Conversely, in the aging females, muscle atrophy expressed relative to body weight decreased in the aged (26-month animals) and then remained constant thereafter (Fig 1). This finding is supported by lannuzzi-Sucich, (2002) who examined appendicular skeletal mass by dual x-ray absorptiometry in men and women and concluded that muscle atrophy varies with aging across gender in humans [81]. Why the degree of muscle loss with aging might vary across gender is not known. To our knowledge this finding in the F344/BN rat strain has not be reported before. In an

effort to understand these phenomena better, we examined how aging may affect the regulation of molecules previously found to be involved mediating muscle adaptation.

Protein kinase B (Akt) plays a number of roles that may be important in sarcopenia [67, 91, 92] including the suppression of apoptosis and modulation of muscle-specific protein degradation via the inhibition of the expression of the ubiquitin E3 ligases atrogin- 1 and MuRF-1. In addition, increased Akt phosphorylation (activity) also promotes protein translation via the inhibition of glycogen synthase kinase-3 and the activation of mTOR[67]. The factors and pathways that regulate Akt are not totally understood but it has been shown that Akt activity is increased with the phosphorylation of Thr308 and Ser473 [92]. With aging we found that Akt phosphorylation (Ser 308 and Ser 473) was increased in the female soleus at 26- and 30-months and in the aging female EDL at 26-months. Conversely, Akt phosphorylation was not increased with aging in the male or in the diaphragm irrespective of gender. Why aging tended to increase Akt phosphorylation in the female but not in the male animals is not known. In addition, why Akt phosphorylation was not altered in the aging diaphragm is also not clear. Nonetheless, these data suggest that Akt is regulated with aging differently between muscle types and genders.

To confirm these data, we next examined how aging may affect the regulation of mTOR. The mammalian target of rapamycin, mTOR is a Ser/Thr protein kinase[93-95], that is thought to lie downstream of Akt [96] and thought to act as a sensor for ATP and amino acids [97]. Under anabolic conditions, mTOR functions to increase translational activity by its ability to activate p70S6K and relieve the repression of 4E-BP1 [98]. Similar to our findings for Akt, we found an increased phosphorylation (activation) of

mTOR in the aging female soleus (Fig 4A). Conversely, mTOR phosphorylation was not increased in the aging male or in the diaphragm muscles of either gender.

Similar to our findings for Akt and mTOR, the phosphorylation of p70S6k also appears to be regulated differently with aging and gender. Here we observe that the amount of phosphorylated p70S6k increases in the soleus of aging male and female animals (Fig 5A.) while it also appears to be elevated in the diaphragm of aging male animals (Fig. 5C). It has been shown that p70S6k plays a critical role in the translation of transcripts involved in the cell cycle progression and the translational machinery [99]. We suggest that this increased phosphorylation observed in the aged soleus indicates that the protein anabolism mechanism is intact up to and including p70S6k. As such, we believe that our data indicates that the aged soleus muscle is fully capable of elevated protein synthesis. Importantly, these data may also suggest that the differences in the loss of muscle mass with age in female animals may be attenuated compared to those observed in male animals. Taken further, these data collectively suggest that the elevation of protein synthetic potential in the face of sarcopenia observed in the present study indicates that a deficiency in the signals used to initiate protein anabolism is not the primary cause of sarcopenia in these animals. Whether other physiological mechanisms may be participating in age-associated muscle loss in this model is actively being pursued in our laboratory.

Aging increases the muscle content of calcineurin

Besides factors that may be directly involved in the regulation of protein synthesis, we also investigated the age-associated expression of calcineurin (CnA).

30

Calcineurin is a Ca2+/calmodulin-dependent protein serine/threonine phosphatase, is a mediator of Ca2+ signaling in different cell systems [100]. CnA has been implicated in the regulation of satellite cell fusion and in the control of myosin heavy chain expression [64, 101-103]. The function of calcineurin in skeletal muscle is not entirely understood, however, previous data have demonstrated that this calcium-sensitive phosphatase acts to dephosphorylate а family of transcription factors called NFAT. This dephosphorylation in turn is thought to activate NFAT by unmasking a nuclear localization signal allowing the movement of NFAT into the nucleus [62]. Calcineurin signaling has been implicated in a broad spectrum of cellular processes including cellcycle regulation and apoptosis while it has been shown that calcineurin is required for proper cardiovascular and skeletal muscle development [104, 105]. In skeletal muscle, calcineurin is thought to regulate the expression of slow myosin heavy chain [106]. Compared to adult (6-month) animals, we observed age-associated increases in the amount of calcineurin levels in each of the muscles examined irrespective of gender (Fig 6). Why aging may increase calcineurin levels is not known, however recent data suggests that aging in humans and the F344/BN rat model is associated with an increase in the amount of slow myosin heavy chain expression [97]. Although not measured in the present study, it is likely that the age-associated increase in calcineurin we observe here may be related to changes in the amount of slow myosin heavy chain expression. Future studies designed to directly test this assertion are currently ongoing.

In summary, we demonstrate that aging has a profound effect on the mass of the F344/BN EDL and soleus muscles. Because the ages of the oldest animals used in the current study correspond roughly to humans in their eighth decade, these data are

31

consistent with the hypothesis that the F344/BN strain is an excellent model for the study of age associated changes in human muscle and for the study of sarcopenia. In addition, we also show that the expression of the muscle plasticity regulators, Akt, mTOR, p70^{S6k}, and calcineurin are regulated differently between muscle types and across gender during aging. In addition, our data also suggest that the activation of these molecules occurs during the progression of muscle atrophy. Taken together, these data suggest that alterations in the expression and / or activation of these molecules are, by themselves, not sufficient to explain why skeletal muscle wasting occurs with aging. Future research aimed at examining other pathways or molecules will no doubt be of interest in helping to increase our understanding of age-associated muscle atrophy.

ACKNOWLEDGEMENTS

This study was supported by National Institute on Aging grant to Eric Blough, Marshall University and by NSF EPSCoR grant to Marshall University.

FIGURE AND FIGURE LEGENDS

This section presents all the figures used in this thesis document and the legends explaining the figures.






Figure 2. Muscle to body weight ratio of: A) Soleus B) EDL of 6- (young adult), 30-(aged) and 36-month (very aged) male and 6- (young adult), 26- (aged) and 30-month (very aged) female Fischer 344/Brown Norway F1 hybrid rats. The data are presented as percent of the 6 month value (n = 4). * indicates significant difference from the corresponding 6 month value, † significantly different with 26- or 30-month animals within the same gender and # significantly different from age-matched males, (p < 0.05).






Figure 3. Tissue content of phospho Akt (Ser308)/ Total Akt/ GAPDH in: A) Soleus B) EDL and, C) Diaphragm in 6 month (young adult), 30 month (aged) and 36 month (very aged) male and 6 month (young adult), 26 month (aged) and 30 month (very aged) female Fischer 344/Brown Norway F1 hybrid rats. Relative changes in protein levels were determined by Western blot analysis. The data are presented as percent of the 6 month value (n = 4). An asterisk indicates significant difference from the corresponding 6 month value, a dagger symbol indicates a difference with 30- or 26-month animals with in the gender and a number symbol indicates a significant difference across the gender, (p < 0.05).








Figure 4. Tissue content of phospho Akt (Ser473)/ Total Akt/ GAPDH in: A) Soleus B) EDL and, C) Diaphragm in 6 month (young adult), 30 month (aged) and 36 month (very aged) male and 6 month (young adult), 26 month (aged) and 30 month (very aged) female Fischer 344/Brown Norway F1 hybrid rats. Relative changes in protein levels were determined by Western blot analysis. The data are presented as percent of the 6 month value (n = 4). An asterisk indicates significant difference from the corresponding 6 month value, a dagger symbol indicates a difference with 30- or 26-month animals with in the gender and a number symbol indicates a significant difference across the gender, (p < 0.05).










Figure 5. Tissue content of phospho mTOR/ Total mTOR/ GAPDH in: A) Soleus B) EDL and, C) Diaphragm in 6 month (young adult), 30 month (aged) and 36 month (very aged) male and 6 month (young adult), 26 month (aged) and 30 month (very aged) female Fischer 344/Brown Norway F1 hybrid rats. Relative changes in protein levels were determined by Western blot analysis. The data are presented as percent of the 6 month value (n = 4). An asterisk indicates significant difference from the corresponding 6 month value, a dagger symbol indicates a difference with 30- or 26-month animals with in the gender and a number symbol indicates a significant difference across the gender, (p < 0.05).








Figure 6. Tissue content of phospho p70S6k (Ser389)/ Total p70S6k/ GAPDH in: A) Soleus B) EDL and, C) Diaphragm in 6 month (young adult), 30 month (aged) and 36 month (very aged) male and 6 month (young adult), 26 month (aged) and 30 month (very aged) female Fischer 344/Brown Norway F1 hybrid rats. Relative changes in protein levels were determined by Western blot analysis. The data are presented as percent of the 6 month value (n = 4). An asterisk indicates significant difference from the corresponding 6 month value, a dagger symbol indicates a difference with 30- or 26month animals with in the gender and a number symbol indicates a significant difference across the gender, (p < 0.05).










Figure 7. Tissue content of calcineurin/ GAPDH in: A) Soleus B) EDL and, C) Diaphragm in 6 month (young adult), 30 month (aged) and 36 month (very aged) male and 6 month (young adult), 26 month (aged) and 30 month (very aged) female Fischer 344/Brown Norway F1 hybrid rats. Relative changes in protein levels were determined by Western blot analysis. The data are presented as percent of the 6 month value (n = 4). An asterisk indicates significant difference from the corresponding 6 month value, a dagger symbol indicates a difference with 30- or 26-month animals with in the gender and a number symbol indicates a significant difference across the gender, (p < 0.05).

Figure 8

-							
	So	leus	E	DL	Diaphragm		
-	Male	Female	Male	Female	Male	Female	
p-Akt(308)	-	↑	-	\downarrow	-	-	
p-Akt(473)	-	ſ	-	-	-	-	
p-mTOR	\downarrow	ſ	\downarrow	-	-	-	
p-p70S6k(389)	1	ſ	\downarrow	-	1	-	
Calcineurin	↑	î	1	1	1	Ť	

Figure 8. Summary of the results for all the molecules in : A) Soleus B) EDL and, C) Diaphragm in 6-month (adult), 30-month (aged) and 36-month (very aged) male and 6-month (adult), 26-month (aged) and 30-month (very aged) female Fischer 344/Brown Norway F1 hybrid rats. The very aged group (36- and 30-month males and females respectively) data are presented as a comparison with the 6 month value. '-' indicates no significant difference from the corresponding 6-month value. ' \uparrow ' indicates a significant decrease with age.

CHAPTER IV

CONCLUSIONS

- Aging affects the regulation of molecules thought to be involved in affecting muscle plasticity differently in different muscles and across genders. Specifically, we observed different alterations across genders in the amount and basal phosphorylation of Akt, mTOR, and p70S6k in the slow twitch-soleus, fast twitch-EDL, and continuously active diaphragm.
- Differences in the regulation of the molecules thought to govern protein synthesis between aging male and female animals may help to explain why the extent of muscle atrophy differs with gender in the F344/BN rats.
- 3. The alterations in Akt, mTOR and p70S6k observed with aging in the skeletal muscles of F344/BN rats suggest that a decrease in the signal to initiate protein synthesis is not the cause of sarcopenia.
- 4. The increase in the expression levels of calcineurin suggests that there may be a phenotypic transformation from fast twitch-type II to slow twitch-type I with age in the soleus, EDL and diaphragm of male and female F344/BN rats.

FUTURE DIRECTIONS

Future directions for research based on this study should focus on the mechanisms involved in the protein degradation, factors causing apoptosis, and the effects of reactive oxygen species on the initiation and progression of muscle atrophy with aging.

We observed an increase or no change in the expression of anabolic biomarkers of protein synthesis with aging in F344/BN male and female rats. This suggests that a decrease in protein synthesis may not be a cause for induction and progression of sarcopenia. To further investigate this possibility, it may be useful to examine other upstream molecules that may be involved in regulating protein synthesis in muscle. Examples here include phosphatase and tensin homolog 10 (PTEN), insulin like growth factor-1 (IGF-1) or the mitogen activated protein kinases (MAPK). Further, it is well known that the total protein content of a tissue is regulated by a balance between the protein synthesis and protein degradation[107, 108]. As such, examining the regulation of protein degradation pathways may also reveal new and interesting information for understanding how aging affects skeletal muscle. Looking into the expression of the biomarkers involved in protein degradation mechanisms may be valuable to understand the incidence of sarcopenia.

The free radical theory of aging states that there is an increase in the concentration of reactive oxygen species (ROS) with age[109]. It is thought that increased ROS may be positively associated with protein degradation[110]. To address this possibility, the effects of these reactive oxygen species with aging in the skeletal muscle could be analyzed by oxyblot analysis and/or by some immunohistochemical methods such as

50

hydroethidium staining. Additional data regarding how aging affects ROS levels in the skeletal muscles of aging male and female F344/BN rats will no doubt be useful in increasing our understanding of muscle atrophy in these animals.

With aging we observed an increase in the expression of calcineurin in all the muscles we examined. Given the positive correlation between calcineurin levels and slow myosin heavy chain expression, future efforts could examine the effects of aging on myosin heavy chain expression [111]. The finding of an increased slow myosin at time points exhibiting augmented calcineurin expression may be useful in determining if this molecule plays a role in modulating age-associated changes in muscle phenotype.

APPENDIX

This section includes table showing body weights, muscle weights and muscle to body weight ratio, and film properties reports, raw data tables, and statistics of various molecules in soleus, EDL, and diaphragm muscles used this study.

Table 1

			Avg.Soleus to		Avg.EDL to
	Body Wt(g)	Soleus(mg)	Body wt ratio (mg/g)	EDL(mg)	Body wt ratio (mg/g)
MALE					
6m	422.50±42.34	168.38±12.66	0.40±0.01	182.88±12.29	0.43±0.01
30m	551.00±21.32	178.38±14.23	0.32±0.02 *	176.88±1.93	0.32±0.01 *
36m	465.00±17.09	122.88±19.55	0.26±0.03 * †	127.75±6.96	0.27±0.01 * †
FEMALE					
6m	228.00±15.06	109.13±12.92	0.48±0.02 #	115.88±11.34	0.51±0.02 #
26m	322.25±44.80	116.38±16.01	0.36±0.04 *	124.63±1.84	0.39±0.03 * #
30m	310.00±19.87	111.75±3.86	0.36±0.01 *	114.25±19.21	0.37±0.02 * #

Table 1. Muscle to body weight ratio of: A) Soleus B) EDL of 6- (young adult), 30-(aged) and 36-month (very aged) male and 6- (young adult), 26- (aged) and 30-month (very aged) female Fischer 344/Brown Norway F1 hybrid rats. The data are presented as percent of the 6 month value (n = 4). * indicates significant difference from the corresponding 6 month value, † significantly different with 26- or 30-month animals within the same gender and # significantly different from age-matched males, (p < 0.05).

SOLEUS

Laboratory of Molecular Physiology Western Blot Film Record

Experimenter	Satyana	rayana Paturi								Print Form
Date 2008/06/30		5/30	Project /	Aging and Aortic Stiffness						
Report Number ASMSOL-01		Tissue/ cell line/ etc.	=1 SO	IEUS - C	ytosolic Fr	action				
Gel type	10%		Electrophoresis Voltag	je 1	24		Trar	nsfer Voltage	25	
Protien Load per Wel	50 ug		Duration	0	1 : 30 hrs		_	Duration	45 r	ninutes
Primary Antibo	ody					Second	lary A	ntibody		
Name (Do Not Abbre	viate) l	^o rotein kinase - B (AKT)				Name	Anti-Ra	ibbit		
Dilution 1:1000	-	Medium	5% BSA in TBST			Dilution	1:1000	м	edium	5% milk in TBST
Incubation time O	/ernight		21			Incubatio	n time	1:00hr		

Lane #1	Lane # 2	Lane # 3	Lane # 4	Lane # 5	Lane # 6	Lane # 7	Lane # 8	Lane # 9	Lane # 10	Lane # 11	Lane # 12
BL	MW	6m Male	30m Male	36m Male	Sample Buffer	6m Female	26m Female	30m Female	Sample Buffer	Positive Control	Sample Buffer

60 1°(1:1000) AKt 2°(1:1000) Ant: Rabbit 06/30/2008 Paturi	
Place Scan of Film Here Used For Analy	rsis
Location of Scan \\Blough-raid\exp-data\Project folder\Aging & aortic stiffness\FILMS\SOLEUS\Akt	
Location of Excel Data \\Blough-raid\exp-data\Project folder\Aging & aortic stiffness\Excel\SOLEUS	
Notes	
email Report	1

Laboratory of Molecular Physiology, Marshall University, Science Bldg. Suite 311, 1 John Marshall Drive, Huntington, WV, 25755 * Phone: 304-696-3267 Fax: 304-696-7136 http://www.science.marshall.edu/blough

Raw data

This section represents the raw data tables produced from spot densitometry of the immunoblot films.

	6m male	30m male	36m male	6m female	26m female	30m female
	17.00	18.80	12.20	15.60	20.00	16.50
	16.80	18.80	12.20	15.80	19.80	16.60
	18.60	19.30	15.00	14.10	15.40	17.50
	18.70	19.50	15.00	13.90	15.10	17.80
	16.80	18.80	12.20	15.80	19.80	16.60
	18.70	19.50	15.00	13.90	15.10	17.80
Ν	6	6	6	6	6	6
Mean	17.77	19.12	13.60	14.85	17.53	17.13
STDEV	0.99	0.35	1.53	0.97	2.56	0.63
SEM	0.44	0.16	0.69	0.44	1.14	0.28

Statistics

Two Way Analysis of Variance

Comparisons for t	factor: Age with	in M			
Comparison	Diff of Means	р	q	Р	P<0.05
30.000 vs. 36.000	5.517	3	9.824	< 0.001	Yes
30.000 vs. 6.000	1.350	2	2.404	0.100	No
6.000 vs. 36.000	4.167	2	7.420	< 0.001	Yes
Comparisons for t	factor: Age with	in F			
Comparison	Diff of Means	р	q	Р	P<0.05
30.000 vs. 6.000	2.683	3	$4.\bar{7}78$	0.006	Yes
30.000 vs. 36.000	0.400	2	0.712	0.618	No
36.000 vs. 6.000	2.283	2	4.066	0.008	Yes
Comparisons for t	factor: Sex withi	n 6			
Comparison	Diff of Means	р	q	Р	P<0.05
M vs. F	2.917	2	5.194	0.001	Yes
Comparisons for t	factor: Sex withi	n 30			
Comparison	Diff of Means	р	q	Р	P<0.05
M vs. F	1.583	2	2.820	0.055	No
Comparisons for t	factor: Sex withi	n 36			
Comparison	Diff of Means		a	Р	P<0.05
F vs. M	3.533	р 2	q 6.292	<0.001	Yes

Laboratory of Molecular Physiology Western Blot Film Record

Experimenter	Jacyo	anarayana	ratun								nt Form	
Date	2008	/06/30		Projec	t	Aging an	d Aortic Stiffr	ness				
Report Number	ASMS	SOL-01		Tissue	e/ cell line/ etc	F1 SOLEU	JS - Cytosolic	Fraction				
Gel type	109	%		Electro	Electrophoresis Voltage 124 Tran					nsfer Voltage 25		
Protien Load per W	ell 50	ug		Durati	Duration 01:30 hrs			<u>14</u>	Duration 45 minutes			
Primary Antil	oody				Secondary A					Antibody		
Name (Do Not Abb	15.0) phosph	o protein kir	nase - B (p-A	kt-308)		Name	Anti-Ral	bbit			
Dilution 1:1000 Medium				ım 5% BSA	A in TBST		Dilution	1:500	M	edium 5% r	nilk in TBST	
Incubation time					Incubat	ion time	1:00hr					
Lane #1 Lane	#2 l	Lane # 3	Lane # 4	Lane # 5	Lane # 6	Lane # 7	Lane # 8	Lane # 9	Lane # 10	Lane # 11	Lane # 12	
BL MV	/ 6	6m Male	30m Male	36m Male	Sample Buffer	6m Female	26m Female	30m Female	Sample Buffer	Positive Control	Sample Buffer	
			+	Ma Ma 6 .30	9 - 30 20 21 ([-) Ferm 6 28	5 10 21-5 -30			Exposure t 10' Molecular V		
				AGINO Ma 6 .30	530 20 20	[> Ferm 6 28	5 10 21.5 .30	*				
		Plac	e Scan of F	10 [-30/	500) /- 1208	L -) Econo 6 26 - AK: Re Par	10 205 30 7308 2554 2004			10' Molecular V	Vieght	
Location of Scan				ilm Here	500) /-	- Pal	T 308 500 500 500 500 500 500 500 500 500 5	SOLEUS\p-4		10' Molecular V 60	Vieght	
	ata	\\Blough	i-raid\exp-da	IO] -30 Film Here	2008	& aortic stiff				10' Molecular V 60	Vieght	
Location of Scan Location of Excel D Notes	ata	\\Blough	i-raid\exp-da	IO] -30 Film Here	older\Aging &	& aortic stiff				10' Molecular V 60	Vieght	

Raw data

This section represents the raw data tables produced from spot densitometry of the immunoblot films.

	6m male	30m male	36m male	6m female	26m female	30m female
	0.94	0.55	0.46	0.44	0.87	2.65
	0.89	0.53	0.47	0.45	0.86	2.71
	1.00	1.11	1.43	0.67	0.87	0.89
	0.61	0.96	1.49	0.64	1.37	1.00
	1.16	0.93	0.92	0.94	0.77	1.22
	1.17	0.93	0.93	0.89	0.77	1.23
Ν	6	6	6	6	6	6
Mean	0.96	0.84	0.95	0.67	0.92	1.62
STDEV	0.21	0.24	0.45	0.21	0.23	0.84
SEM	0.09	0.11	0.20	0.09	0.10	0.37

Statistics

Two Way Analysis of Variance

Comparisons for a Comparison M vs. F		in 6 p 2	q 1.680	P 0.244	P<0.05 No
Comparisons for a Comparison F vs. M	factor: SEX with Diff of Means 0.0822	in 3 p 2	q	P 0.741	P<0.05 No
Comparisons for a Comparison F vs. M	factor: SEX with Diff of Means 0.669	in 3 p 2	6 q 3.842	P 0.011	P<0.05 Yes
Comparisons for	factor: AGE witl	hin N	Л		
Comparison	Diff of Means	р	q	Р	P<0.05
6.000 vs. 30.000	0.126	3	0.724	0.866	No
6.000 vs. 36.000	0.0146	2	0.0839	0.953 E	Do Not Test
36.000 vs. 30.000	0.111	2	0.640	0.654 E	Do Not Test
Comparisons for	factor: AGE witl	hin H	7		
Comparison	Diff of Means	р	q	Р	P<0.05
36.000 vs. 6.000	0.947	3	5.438	0.002	Yes

2 4.010

2 1.428

0.008

0.321

0.698

0.249

Yes

No

36.000 vs. 30.000

30.000 vs. 6.000

Laboratory of Molecular Physiology Western Blot Film Record

Experimenter	Satyanaraya									
Date	2008/06/30		Projec	t	Aging an	d Aortic Stiffn	ness			
Report Number	ASMSOL-01		Tissue	e/ cell line/ et	c. F1 SOLEU	S - Cytosolic	Fraction			
Gel type	10%		Electro	Electrophoresis Voltage 124			Transfer Voltage 25			
Protien Load per W	ell 50 ug		 Durati	Duration 01:30 hrs						es
Primary Antil	adv		<u></u>	Secondary Ant			ntibody			
Name (Do Not Abb	07.17	oho protein ki	nase - B (p-A	kt-473)		Name	Anti-Ra			
Dilution 1:1000		Mediu		A in TBST		 Dilution			edium 5% r	nilk in TBST
	Overnight			generality and preservations		 Incubati	ion time	1:00hr	and the second s	
Lane #1 Lane	#2 Lane#3	Lane # 4	Lane # 5	Lane # 6	Lane # 7	Lane # 8	Lane # 9	Lane # 10	Lane # 11	Lane # 12
BL MV			36m Male	Sample Buffer	6m Female	26m Female	30m Female	Sample Buffer	Positive Control	Sample Buffer
		Sol	ens - ale og m	() - !	Femal V 78	100			Exposure t 10' Molecular V	
		Acce Scan of	o phosp Film Here	no Att Pate		2 60 			10'	Vieght
Location of Scan			o phosp Film Here	no Att Pate			OLEUS\p-/		10' Molecular V 60	Vieght
	\\Blou	Acce Scan of	م ج ب ب ب ب ب ب ب ب ب ب ب ب ب ب ب ب ب ب	he Att Patu older\Aging	& aortic stiff	ness\FILMS\S			10' Molecular V 60	Vieght
Location of Scan Location of Excel D Notes	\\Blou	A A A A A A A A A A A A A A A A A A A	م ج ب ب ب ب ب ب ب ب ب ب ب ب ب ب ب ب ب ب	he Att Patu older\Aging	& aortic stiff	ness\FILMS\S			10' Molecular V 60	Vieght

Laboratory of Molecular Physiology, Marshall University, Science Bldg. Suite 311, 1 John Marshall Drive, Huntington, WV, 25755 * Phone: 304-696-3267 Fax: 304-696-7136 http://www.science.marshall.edu/blough

Raw data

This section represents the raw data tables produced from spot densitometry of the immunoblot films.

	6m male	30m male	36m male	6m female	26m female	30m female
	0.94	0.55	0.46	0.44	0.87	2.65
	0.89	0.53	0.47	0.45	0.86	2.71
	1.18	0.94	0.93	0.88	0.76	1.25
	0.80	0.51	0.38	0.51	1.13	2.53
	1.16	0.93	0.92	0.94	0.77	1.22
	1.17	0.93	0.93	0.89	0.77	1.23
Ν	6	6	6	6	6	6
Mean	1.02	0.73	0.68	0.68	0.86	1.93
SD	0.17	0.22	0.27	0.24	0.14	0.77
SEM	0.07	0.10	0.12	0.11	0.06	0.34

Statistics

Two Way Analysis of Variance

Comparisons for f	actor: SEX with	in 6				
Comparison	Diff of Means	р	q	Р	P<0.05	
M vs. F	0.339	2	2.254	0.122	No	
Comparisons for f	actor: SEX with	in 3	0			
Comparison	Diff of Means	р	q	Р	P<0.05	
F vs. M	0.128	2	0.848	0.553	No	
Comparisons for f	actor: SEX with	in 3	6			
Comparison		р	-	Р	P<0.05	
F vs. M	1.252	2	8.319	< 0.001	Yes	
Comparisons for f	actor: AGE with	nin N	A			
Comparison	Diff of Means	р	q	Р	P<0.05	
6.000 vs. 36.000	0.344	3	2.287	0.254	No	
6.000 vs. 30.000	0.290	2	1.929	0.183 I	Do Not Test	
30.000 vs. 36.000 0.0538			0.357	0.802 Do Not Test		
Comparisons for f	actor: AGE with	nin H	<u>ר</u>			
Comparison	Diff of Means	р	q	Р	P<0.05	
36.000 vs. 6.000	1.248		_	< 0.001	Yes	
a < 000 a 000	4 0 - 4	•	- 110	0.001	T 7	

L			-		
36.000 vs. 6.000	1.248	3	8.286	< 0.001	Yes
36.000 vs. 30.000	1.071	2	7.113	< 0.001	Yes
30.000 vs. 6.000	0.177	2	1.173	0.414	No

Laboratory of Molecular Physiology Western Blot Film Record

	≘r Sa 	tyanarayana	Paturi							Pfir	nt Form
Date 2008/04/24 Report Number ASMSOL-01		Projec	:t	Aging an	d Aortic Stiffr	ness					
		Tissue	Tissue/ cell line/ etc. F1 SOLEUS - Cytosolic Fraction								
Gel type 10% Protien Load per Well 50 ug			Electro	Electrophoresis Voltage 124			Tran	sfer Voltage	25		
			Durati	Duration 01:30			0 hrs Duration			45 minutes	
Primary .	Antibod	у					Secor	ndary A	ntibody		
lame (Do N	lot Abbrevia	ite) mamm	alian target o	of rapamycir	n (mTOR)		Name	Anti-Ral	bbit		
ilution 1:	1000	13	Mediu	ım 5% BS/	5% BSA in TBST			1:1000	Medium 5% milk		nilk in TBS
ncubation t	ime Over	night		ά.			Incubat	ion time	1:00hr	6.	
Lane #1	Lane # 2	Lane # 3	Lane # 4	Lane # 5	Lane # 6	Lane # 7	Lane # 8	Lane # 9	Lane # 10	Lane # 11	Lane # 12
BL	MW	6m Male	30m Male	36m Male	Sample Buffer	бт Female	26m Female	30m Female	Sample Buffer	Positive Control	Sample Buffer
			-	-		CHAIF	5			MolecularV	Vieght
			ce Scan of F	Film Here	- 30L 10) mi 10) Ant 3		sit			Molecular V 289 Used Fo	
ocation of s	Scan		ce Scan of F	Film Here	older/Aging	f17) TOR. Rable	sit	5OLEUS\p-r		289	_
		\\Blough	ce Scan of F	Film Here ata\Project f	- 30L 10) mi 10) Ant 3	ATTOR TOR Rath	ness\FILMS\\$			289	
ocation of s ocation of I lotes		\\Blough	ce Scan of F	Film Here ata\Project f	- JOL 0) m 0) Ant 3	ATTOR TOR Rath	ness\FILMS\\$			289	_
ocation of I		\\Blough	ce Scan of F	Film Here ata\Project f	- JOL 0) m 0) Ant 3	ATTOR TOR Rath	ness\FILMS\\$		mTOR	289	r Analysis

	6m male	30m male	36m male	6m female	26m female	30m female
	18.60	12.90	16.30	20.90	12.40	18.90
	18.70	12.80	16.40	20.80	12.60	18.70
	15.30	11.70	16.90	23.80	15.60	16.70
	15.20	11.50	17.10	23.80	15.70	16.70
	16.10	12.70	15.70	21.10	14.80	19.60
	16.10	12.50	15.70	21.30	14.90	19.50
N	6	6	6	6	6	6
Mean	16.67	12.35	16.35	21.95	14.33	18.35
SD	1.58	0.60	0.59	1.44	1.47	1.32
SEM	0.71	0.27	0.26	0.65	0.66	0.59

Two Way Analysis of Variance

Comparisons for factor: Age within M	Comparisons	for factor:	Age within M
--------------------------------------	-------------	-------------	--------------

Comparison	Diff of Means	р	q	Р	P<0.05
6.000 vs. 30.000	4.317	3	8.542	< 0.001	Yes
6.000 vs. 36.000	0.317	2	0.627	0.661	No
36.000 vs. 30.000	4.000	2	7.915	< 0.001	Yes

Comparisons for factor: Age within F										
Comparison	Diff of Means	р	q	Р	P<0.05					
6.000 vs. 30.000	7.617	3	15.072	< 0.001	Yes					
6.000 vs. 36.000	3.600	2	7.124	< 0.001	Yes					
36.000 vs. 30.000	4.017	2	7.948	< 0.001	Yes					

Comparisons for factor: Sex within 6									
Comparison	Diff of Means	р	q	Р	P<0.05				
F vs. M	5.283	2	10.455	< 0.001	Yes				

Comparisons for factor: Sex within 30									
Comparison	Diff of Means	р	q	Р	P<0.05				
F vs. M	1.983	2	3.925	0.010	Yes				

Comparisons for factor: Sex within 36									
Comparison	Diff of Means	р	q	Р	P<0.05				
F vs. M	2.000	2	3.958	0.009	Yes				

	Sat	tyanarayana	Paturi							Prir	it Form
Date	20	08/04/24		Projec	t	Aging and	d Aortic Stiffr	iess			
Report Number	AS	MSOL-01		Tissue	/ cell line/ et	c. F1 SOLEU	S - Cytosolic	Fraction			
Gel type	1	10%		Electro	Electrophoresis Voltage 124 Transfer			sfer Voltage	25		
Protien Load per V	Vell 5	50 ug		 Durati		01:3	0 hrs	<u></u>	Duration	45 minute	25
Primary Anti	hod	v				<u>1</u>	Secor	dary Ai	ntibody		
Name (Do Not Ab			no mammalia	an target of I	rapamvcin (r	o-mTOR)	Name	Anti-Ral	17.0		
Dilution 1:1000			Mediu	e terrete entretere	A in TBST		 Dilution	1:1000	Me	dium 5% n	nilk in TBS ⁻
ncubation time	Over	night					 Incubat	ion time	1:00hr	<u>.</u>	
Lane #1 Lane	2 # 2	Lane # 3	Lane # 4	Lane # 5	Lane # 6	Lane # 7	Lane # 8	Lane # 9	Lane # 10	Lane # 11	Lane # 12
BL M	w	6m Male	30m Male	36m Male	Sample Buffer	6m Female	26m Female	30m Female	Sample Buffer	Positive Control	Sample Buffer
		Plac	ce Scan of F		6, <u>6</u> Fe Anti 21/2008	26 30, males TOR Rabbill Fate	ui		J	Molecular V 289 ▼ Used Fo	
									nTOR		r Analysis
ocation of Scan		\\Blough	n-raid\exp-da	ata\Project f	older\Aging	& aortic stiff	ness\FILMS\S	OLEUS\p-r			r Analysis
ocation of Scan	Data		824 D.	7.7 N D 24			ness\FILMS\S ness\Excel\S0	1974 4			r Analysis
	Data		824 D.	7.7 N D 24			101 V/	1974 4			r Analysis

	6m male	30m male	36m male	6m female	26m female	30m female
	0.85	1.28	0.76	0.54	1.28	1.49
	0.89	1.30	0.77	0.49	1.28	1.50
	1.25	1.06	0.79	0.58	1.06	1.49
	1.24	1.10	0.76	0.58	1.04	1.51
	1.34	0.70	0.57	0.96	1.07	1.26
	1.04	0.87	1.18	0.99	0.62	1.21
Ν	6	6	6	6	6	6
Mean	1.10	1.05	0.80	0.69	1.06	1.41
SD	0.20	0.23	0.20	0.22	0.24	0.14
SEM	0.09	0.10	0.09	0.10	0.11	0.06

Two Way Analysis of Variance

Comparisons for factor: SEX within 6										
Comparison	Diff of Means	р	q	Р	P<0.05					
M vs. F	0.414	2	4.839	0.002	Yes					
Comparisons for fa Comparison F vs. M	actor: SEX with Diff of Means 0.00825	in 3 p 2	0 q 0.0965	P 0.946	P<0.05 No					
Comparisons for factor: SEX within 36										
Comparison	Diff of Means	р	q	Р	P<0.05					
F vs. M	0.606	2	7.088	< 0.001	Yes					
Comparisons for fa			М	-	-					
-	Diff of Means	р	q	Р	P<0.05					
6.000 vs. 36.000	0.299	3	3.490	0.050	Yes					
6.000 vs. 30.000	0.0515	2	0.602	0.674	No					
30.000 vs. 36.000	0.247	2	2.888	0.050	No					
Comparisons for factor: AGE within F										
-	Diff of Means	р	q	Р	P<0.05					
36.000 vs. 6.000	0.722	3	8.436	< 0.001	Yes					
36.000 vs. 30.000	0.351	2	4.103	0.007	Yes					

2 4.333

0.371

0.005

Yes

30.000 vs. 6.000

	Sat	tyanarayana	Paturi							Prir	nt Form
Date	20	08/04/24		Projec	t	Aging an	d Aortic Stiffr	iess			
Report Numbe	er AS	MSOL-01		Tissue	e/ cell line/ et	c. F1 SOLEU	IS - Cytosolic	Fraction			
Gel type		10%		Electro	Electrophoresis Voltage 124 Transfer Voltage					25	
Protien Load p	oer Well	50 ug		 Durati		1053 S	0 hrs		Duration	45 minute	25
20 2				<u></u>		12	Sacor		ntibody		
Primary A Name (Do Not			somal Protei	in(n7056k)			Name	Anti-Ral	107.0		
Dilution 1:10			Mediu		5% BSA in TBST Dilution 1:1000				Medium 5% milk in TBST		
Incubation tim	747	night						than coolain T	1:00hr		
	1.0						_				
Lane #1 L	Lane # 2	Lane # 3	Lane # 4	Lane # 5	Lane # 6	Lane # 7	Lane # 8	Lane # 9	Lane # 10	Lane # 11	Lane # 12
BL	MW	6m Male	30m Male	36m Male	Sample Buffer	бт Female	26m Female	30m Female	Positive Control	Sample Buffer	Sample Buffer
						-	X males 26 30'	-	*	Molecular V 70	Vieght
		Plac	See 14		1000) 1000) 2008	P703 Ant: Pa	kabbi tusi	t			ur Analysis
Location of Sci	an		e Scan of F	ilm Here			ness\FILMS\S		Ĩ	Z Used Fo	r Analysis
Location of Sca		\\Blough	ce Scan of F n-raid\exp-da	Film Here ata∖Project f	older\Aging	& aortic stiff		OLEUS	F		or Analysis

Laboratory of Molecular Physiology, Marshall University, Science Bldg. Suite 311, 1 John Marshall Drive, Huntington, WV, 25755 * Phone: 304-696-3267 Fax: 304-696-7136 http://www.science.marshall.edu/blough

	6m male	30m male	36m male	6m female	26m female	30m female
	14.90	21.50	4.20	8.90	27.50	23.00
	14.80	21.70	4.00	8.70	27.60	23.10
	12.10	20.90	7.80	9.60	27.70	21.90
	12.20	20.90	7.70	10.00	27.60	21.60
	16.20	26.70	6.90	5.80	27.10	17.30
	16.30	26.40	7.00	5.80	27.10	17.40
Ν	6	6	6	6	6	6
Mean	14.42	23.02	6.27	8.13	27.43	20.72
SD	1.86	2.76	1.72	1.87	0.27	2.67
SEM	0.83	1.23	0.77	0.84	0.12	1.20

Two Way Analysis of Variance

Comparisons for f	actor: Age withi	in M	[
Comparison	Diff of Means	р	q	Р	P<0.05
30.000 vs. 36.000	16.750	3	20.207	< 0.001	Yes
30.000 vs. 6.000	8.600	2	10.375	< 0.001	Yes
6.000 vs. 36.000	8.150	2	9.832	< 0.001	Yes

Comparisons for f	actor: Age withi	in F			
Comparison	Diff of Means	р	q	Р	P<0.05
30.000 vs. 6.000	19.300	3	23.283	< 0.001	Yes
30.000 vs. 36.000	6.717	2	8.103	< 0.001	Yes
36.000 vs. 6.000	12.583	2	15.180	< 0.001	Yes

Comparisons for factor: Sex within 6										
Comparison	Diff of Means	р	q	Р	P<0.05					
M vs. F	6.283	2	7.580	< 0.001	Yes					

Comparisons for factor: Sex within 30										
Comparison	Diff of Means	р	q	Р	P<0.05					
F vs. M	4.417	2	5.328	< 0.001	Yes					

Comparisons for factor: Sex within 36									
Comparison	Diff of Means	р	q	Р	P<0.05				
F vs. M	14.450	2	17.432	< 0.001	Yes				

Experimenter	Satyanaraya	na Paturi							Pri	nt Form
Date	2008/04/24		Projec	t	Aging an	d Aortic Stiffr	ness			
Report Number	ASMSOL-01		Tissue	e/ cell line/ et	tc. F1 SOLEU	JS - Cytosolic	Fraction			
Gel type	10%		Electro	ophoresis Vo	ltage 124		Tran	sfer Voltage	25	
Protien Load per \	Nell 50 ug		 Durati		1975 B	30 hrs		Duration	45 minut	es
24 22			<u></u>		<u>.</u>	C	dom: A			
Primary Anti Name (Do Not Ab	(*)(aha (6 Dihara	mal Protoin/	-D70066220	9)	Name	Anti-Ra	ntibody		
Dilution 1:1000	breviace) prios	Mediu	-	A in TBST	~1	Dilutior	-		edium 5% I	nilk in TRST
	Overnight	medit					ion time	1:00hr		
Incubation time	Overnight						ontime			
Lane #1 Lane	e#2 Lane#3	Lane # 4	Lane # 5	Lane # 6	Lane # 7	Lane # 8	Lane # 9	Lane # 10	Lane # 11	Lane # 12
BL M	W 6m Male	30m Male	36m Male	Sample Buffer	6m Female	26m Female	30m Female	Positive Control	Sample Buffer	Sample Buffer
	PI	ace Scan of 1		00)p. 00)A 2008	-P703 mt: R Ja	Shk 38 asbit turi	9		Molecular V	Vieght
Location of Scan	\\Blou	gh-raid\exp-da	ata\Project f	older\Aging	& aortic stiff	ness\FILMS\S	OLEUS			
Location of Excel	Data \\Blou	gh-raid\exp-da	ata\Project f	older\Aging	& aortic stiff	ness\Excel\S	OLEUS			
	-									
Notes										
Notes									email Repor	t

Laboratory of Molecular Physiology, Marshall University, Science Bldg. Suite 311, 1 John Marshall Drive, Huntington, WV, 25755 * Phone: 304-696-3267 Fax: 304-696-7136 http://www.science.marshall.edu/blough

	6m male	30m male	36m male	6m female	26m female	30m female
	1.59	1.33	3.93	0.49	0.29	0.83
	1.59	1.30	4.15	0.52	0.29	0.82
	1.62	1.28	2.01	0.39	0.43	1.02
	1.57	1.29	2.05	0.38	0.42	1.06
	1.43	1.02	2.30	0.71	0.37	1.12
	1.18	1.02	2.26	0.66	0.42	1.31
Ν	6	6	6	6	6	6
Mean	1.50	1.21	2.78	0.52	0.37	1.03
SD	0.17	0.14	0.98	0.14	0.07	0.19
SEM	0.08	0.06	0.44	0.06	0.03	0.08

Two Way Analysis of Variance

Comparisons for Comparison M vs. F		in 6 p 2	q 5.650	P <0.001	P<0.05 Yes
Comparisons for				р	D -0.05
Comparison M vs. F	Diff of Means 0.835	р 2	q 4.843	P 0.002	P<0.05 Yes
Comparisons for		in 3	6		
Comparison M vs. F	Diff of Means 1.759	р 2	q 10.204	P <0.001	P<0.05 Yes
Comparisons for	factor: AGE witl	hin N	Л		
Comparisons for Comparison		nin N p	A q	Р	P<0.05
-	Diff of Means		q	P <0.001	P<0.05 Yes
Comparison	Diff of Means	р	q 9.157		
Comparison 36.000 vs. 30.000	Diff of Means 1.578	р 3	q 9.157	< 0.001	Yes
Comparison 36.000 vs. 30.000 36.000 vs. 6.000 6.000 vs. 30.000 Comparisons for	Diff of Means 1.578 1.287 0.291 factor: AGE wit	p 3 2 2	q 9.157 7.468 1.689	<0.001 <0.001 0.242	Yes Yes No
Comparison 36.000 vs. 30.000 36.000 vs. 6.000 6.000 vs. 30.000 Comparisons for Comparison	Diff of Means 1.578 1.287 0.291 factor: AGE with Diff of Means	p 3 2 2 hin F	q 9.157 7.468 1.689	<0.001 <0.001 0.242 P	Yes Yes No P<0.05
Comparison 36.000 vs. 30.000 36.000 vs. 6.000 6.000 vs. 30.000 Comparisons for Comparison 36.000 vs. 30.000	Diff of Means 1.578 1.287 0.291 factor: AGE with Diff of Means 0.654	p 3 2 2 hin F 3	q 9.157 7.468 1.689	<0.001 <0.001 0.242 P 0.031	Yes Yes No P<0.05 Yes
Comparison 36.000 vs. 30.000 36.000 vs. 6.000 6.000 vs. 30.000 Comparisons for Comparison	Diff of Means 1.578 1.287 0.291 factor: AGE with Diff of Means	p 3 2 2 hin F	q 9.157 7.468 1.689	<0.001 <0.001 0.242 P	Yes Yes No P<0.05

Date	10 J. 10 J.	anarayana	racan							Prir	nt Form
Date	200	8/10/16		 Projec	t	Aging and	d Aortic Stiffr	ness			
Report Number	ASN	ISOL-01		Tissue	e/ cell line/ etc	F1 SOLEU	IS - Cytosolic	Fraction			
Gel type	10)%		Electro	ophoresis Volt	age 124		Tran	sfer Voltage	25	
Protien Load pe	rWell 50) ug		 Durati	on	01:3	0 hrs		Duration	45 minute	25
Primary An	tibody	(Secor	ndary Aı	ntibody		
r Name (Do Not A	100		urin A (CnA)				Name	Anti-Ral	bbit		
Dilution 1:100	D		Mediur	n 5% BS/	A in TBST		Dilution	1:1000	M	edium 5% r	nilk in TBST
Incubation time	Overni	ight		ζε.			Incubat	ion time	1:00hr	G.	
Lane #1 La	ne # 2	Lane # 3	Lane # 4	Lane # 5	Lane # 6	Lane # 7	Lane # 8	Lane # 9	Lane # 10	Lane # 11	Lane # 12
BL /	ww	6m Male	30m Male	36m Male	Sample Buffer	6m Female	26m Female	30m Female	Sample Buffer	Positive Control	Sample Buffer
							N ")				
		Plac	the Scan of Fi	1° C C R° Ar Io/IS	alei tim 12008	ren	sin e(1:1 Gn/1] (1:100) 000) Pater		Molecular V 61 Used Fo	
_ocation of Scar	1		e Scan of Fi	ilm Here	alei tim 12008					61	_
Location of Scan		\\Blough	ce Scan of Fi n-raid∖exp-dat	ilm Here :a\Project f		aortic stiff	ness\FILMS\S	SOLEUS\Cal		61	_
ocation of Exce		\\Blough	ce Scan of Fi n-raid∖exp-dat	ilm Here :a\Project f	older\Aging &	aortic stiff	ness\FILMS\S	SOLEUS\Cal		61	_
		\\Blough	ce Scan of Fi n-raid∖exp-dat	ilm Here :a\Project f	older\Aging &	aortic stiff	ness\FILMS\S	SOLEUS\Cal		61	_

	6m male	30m male	36m male	6m female	26m female	30m female
	2.40	16.70	28.80	10.70	20.30	21.10
	2.80	16.50	28.70	10.70	20.30	21.10
	5.90	18.80	24.10	13.50	18.80	19.00
	5.80	18.90	24.20	13.40	18.30	19.40
	16.60	16.60	12.60	10.10	16.10	28.10
	16.60	16.60	12.60	10.10	16.10	28.10
N	6	6	6	6	6	6
Mean	8.35	17.35	21.83	11.42	18.32	22.80
SD	6.55	1.16	7.44	1.60	1.89	4.19
SEM	2.93	0.52	3.33	0.71	0.85	1.88

Two Way Analysis of Variance

Comparisons for f	actor: Age withi	in M			
Comparison	Diff of Means	р	q	Р	P<0.05
36.000 vs. 6.000	13.483	3	7.281	< 0.001	Yes
36.000 vs. 30.000	4.483	2	2.421	0.097	No
30.000 vs. 6.000	9.000	2	4.860	0.002	Yes
Comparisons for f	actor: Age withi	in F			
Comparison	Diff of Means	р	q	Р	P<0.05
36.000 vs. 6.000	11.383	3	6.147	< 0.001	Yes
36.000 vs. 30.000	4.483	2	2.421	0.097	No
30.000 vs. 6.000	6.900	2	3.726	0.013	Yes
Comparisons for f	actor: Sex withi Diff of Means	n 6 p	q	Р	P<0.05
-	Diff of Micans	· · ·	ч		
F VS. M	3.067		_	0.251	
F vs. M Comparisons for f Comparison F vs. M	3.067 Factor: Sex within Diff of Means 0.967	2	q 0.522	0.251 P 0.715	No P<0.05 No
Comparisons for f Comparison F vs. M	actor: Sex withi Diff of Means 0.967	2 n 30 p 2	1.656 q	Р	No P<0.05
Comparisons for f	actor: Sex withi Diff of Means 0.967	2 n 30 p 2	1.656 q	Р	No P<0.05

<u>EDL</u>

Date	Satyanarayan	a Paturi							Prii	nt Form
	2008/04/10		Projec	t	Aging an	d Aortic Stiffr	ness			
Report Number	ASMEDL-01		Tissue	/ cell line/ etc	. F1 EDL - (Cytosolic Frac	tion			
Gel type	12%		Electro	ophoresis Volt	age 124		Tran	nsfer Voltage	25	
Protien Load per W	/ell 50 ug		 Durati	on	01:3	0 hrs		Duration		es
Primary Antik	odv				12	Secor	ndarv A	ntibody	5	
Name (Do Not Abb	(* 11)	n Kinase - B (A	kt)			Name	Anti Ra	1000		
Dilution 1:1000		Mediu		A in TBST		Dilution	1:1000) M	edium 5%	Milk in TBS
ncubation time	Overnight		100			 Incubat	ion time	1 hr	6	
-										
Lane #1 Lane	# 2 Lane # 3	Lane # 4	Lane # 5	Lane # 6	Lane # 7	Lane # 8	Lane # 9	Lane # 10	Lane # 11	Lane # 12
BL MV	V 6m Male	30m Male	36m Male	Sample Buffer	6m Female	26m Female	30m Female	Positive Control	Sample Buffer	Sample Buffer
		-		-		- < 6	0 kde		Molecular N 60 kda	Wieght
	Pla	و م م ce Scan of F	kt (]: ilm Here	1000)		Patie	90 B	ŀ	🗸 Used Fo	or Analysis
ocation of Scan		ce Scan of F	ilm Here	older\Aging 8					🖌 Used Fo	or Analysis
Location of Scan	\\Bloug	ce Scan of F h-raid\exp-da	ilm Here ta\Project f		aortic stiff	ness\FILMS\E	EDL\Akt\Go		Used Fo	or Analysis
	\\Bloug	ce Scan of F h-raid\exp-da	ilm Here ta\Project f	older\Aging 8	aortic stiff	ness\FILMS\E	EDL\Akt\Go		✔ Used Fo	or Analysis

Laboratory of Molecular Physiology, Marshall University, Science Bldg. Suite 311, 1 John Marshall Drive, Huntington, WV, 25755 * Phone: 304-696-3267 Fax: 304-696-7136 http://www.science.marshall.edu/blough

	6m male	30m male	36m male	6m female	26m female	30m female
	13.60	24.80	21.40	9.90	9.70	20.50
	13.90	24.60	21.50	10.00	9.80	20.30
	12.10	15.30	13.40	15.20	21.40	22.60
	12.20	15.30	13.40	15.30	21.30	22.60
	12.70	21.40	18.20	16.40	13.30	18.00
	12.60	21.80	18.30	16.30	13.00	17.90
Ν	6	6	6	6	6	6
Mean	12.85	20.53	17.70	13.85	14.75	20.32
STDEV	0.74	4.29	3.63	3.06	5.33	2.08
SEM	0.33	1.92	1.62	1.37	2.39	0.93

Two Way Analysis of Variance

Comparisons for f	actor: Age withi	n M			
Comparison	Diff of Means	р	q	Р	P<0.05
30.000 vs. 6.000	7.683	3	5.351	0.002	Yes
30.000 vs. 36.000	2.833	2	1.973	0.173	No
36.000 vs. 6.000	4.850	2	3.378	0.024	Yes
Comparisons for f	actor: Age withi	n F			
Comparison	Diff of Means	р	q	Р	P<0.05
36.000 vs. 6.000	6.467	3	4.503	0.009	Yes
36.000 vs. 30.000	5.567	2	3.877	0.010	Yes

Comparisons for	factor: Sex within	n 6			
Comparison	Diff of Means	р	q	Р	P<0.05
F vs. M	1.000	2	0.696	0.626	No

2 0.627

0.661

No

0.900

30.000 vs. 6.000

Comparisons for	factor: Sex within	n 30			
Comparison	Diff of Means	р	q	Р	P<0.05
M vs. F	5.783	2	4.028	0.008	Yes

Comparisons for	factor: Sex within	n 36			
Comparison	Diff of Means	р	q	Р	P<0.05
F vs. M	2.617	2	$1.\bar{8}22$	0.208	No

Experimenter		a Paturi							Prir	nt Form
Date	2008/07/23		 Projec	t	Aging an	d Aortic Stiffr	ness			
Report Number	ASMEDL-01					Cytosolic Frac	tion			
	2									
Gel type	10%			ophoresis Vo	1073 I		Tran	sfer Voltage	1000000 00 00	
Protien Load per W	/ell 50 ug		Durati	on	01:3	0 hrs		Duration	45minute	5
Primary Antib	body					Secor	ndary A	ntibody		
Name (Do Not Abb	oreviate) phosph	no Protein Kii	nase - 308 (p	o - AKT - 308)	C	Name	Anti-Ra	bbit		
Dilution 1:1000		Mediu	ım 5% BSA	A in TBST		Dilution	1:1000	M	edium 5% M	Ailk in TBST
ncubation time	Overnight					Incubat	ion time	1:00 hr		
Lane #1 Lane ;	# 2 Lane # 3	Lane # 4	Lane # 5	Lane # 6	Lane # 7	Lane # 8	Lane # 9	Lane # 10	Lane # 11	Lane # 12
BL MW	V 6m Male	30m Male	36m Male	Sample Buffer	6m Female	26m Female	30m Female	Sample Buffer	Positive Control	Sample Buffer
					10		I.		Molecular V	Vieght
		ce Scan of F	ilm Here	07/2.	3/2008	- 308 abbit- Pater			60	or Analysis
.ocation of Scan			ilm Here	07/2.	3/2008	iness/FILMS/E				or Analysis
	\\Bloug	n-raid\exp-da	Film Here	07/A.	8 aortic stiff	Aster	:DL\p-Akt-			or Analysis
Location of Scan Location of Excel D. Notes	\\Bloug	n-raid\exp-da	Film Here	07/A.	8 aortic stiff	Poteo iness\FILMS\E	:DL\p-Akt-			or Analysis

Laboratory of Molecular Physiology, Marshall University, Science Bldg. Suite 311, 1 John Marshall Drive, Huntington, WV, 25755 * Phone: 304-696-3267 Fax: 304-696-7136 http://www.science.marshall.edu/blough

	6m male	30m male	36m male	6m female	26m female	30m female
	1.41	0.75	0.87	1.31	1.58	0.74
	1.42	0.77	0.89	1.23	1.51	0.74
	0.86	1.00	1.35	1.20	0.82	0.90
	0.78	1.00	1.35	1.23	0.84	0.90
	1.20	0.55	0.96	1.10	1.38	1.07
	1.25	0.58	0.95	1.07	1.37	1.06
N	6	6	6	6	6	6
Mean	1.16	0.78	1.06	1.19	1.25	0.90
SD	0.28	0.19	0.23	0.09	0.33	0.14
SEM	0.12	0.09	0.10	0.04	0.15	0.06

Two Way Analysis of Variance

Comparisons for	factor: SEX with	in 6			
Comparison	Diff of Means	р	q	Р	P<0.05
F vs. M	0.0367	2	0.399	0.780	No
Comparisons for	factor: SEX with	in 3	0		
Comparison	Diff of Means	р	q	Р	P<0.05
F vs. M	0.473	2	5.146	0.001	Yes
Comparisons for	factor: SEX with	in 3	6		
Comparison	Diff of Means	р	q	Р	P<0.05
M vs. F	0.162	2	1.759	0.223	No
111 10.1	0.102			0.225	
111 15. 1	0.102	-	1	0.225	
Comparisons for				0.223	
Comparisons for Comparison	factor: AGE with			P	P<0.05
Comparisons for	factor: AGE with	hin N	И	Р	P<0.05 Yes
Comparisons for Comparison	factor: AGE witl Diff of Means	hin N p 3	∕I q 4.127	Р	
Comparisons for Comparison 6.000 vs. 30.000	factor: AGE witl Diff of Means 0.379 0.0939	hin N p 3	q 4.127 1.021	P 0.018	Yes
Comparisons for Comparison 6.000 vs. 30.000 6.000 vs. 36.000	factor: AGE witl Diff of Means 0.379 0.0939	hin N p 3 2	q 4.127 1.021	P 0.018 0.476	Yes No
Comparisons for Comparison 6.000 vs. 30.000 6.000 vs. 36.000	factor: AGE witl Diff of Means 0.379 0.0939) 0.286	hin N p 3 2 2	q 4.127 1.021 3.105	P 0.018 0.476	Yes No
Comparisons for Comparison 6.000 vs. 30.000 6.000 vs. 36.000 36.000 vs. 30.000	factor: AGE witl Diff of Means 0.379 0.0939 0.286 factor: AGE witl	hin N p 3 2 2	q 4.127 1.021 3.105	P 0.018 0.476	Yes No
Comparisons for Comparison 6.000 vs. 30.000 6.000 vs. 36.000 36.000 vs. 30.000 Comparisons for	factor: AGE with Diff of Means 0.379 0.0939 0.286 factor: AGE with Diff of Means	hin N p 3 2 2 hin H	q 4.127 1.021 3.105	P 0.018 0.476 0.036 P	Yes No Yes
Comparisons for Comparison 6.000 vs. 30.000 6.000 vs. 36.000 36.000 vs. 30.000 Comparisons for Comparison	factor: AGE with Diff of Means 0.379 0.0939 0.286 factor: AGE with Diff of Means	hin N p 3 2 2 hin H p	q 4.127 1.021 3.105	P 0.018 0.476 0.036 P	Yes No Yes P<0.05

Experimenter	Sa	atyanarayana	Paturi							Pri	nt Form	
Date	20	008/04/14		Projec	t	Aging an	d Aortic Stiffr	ness				
Report Numb	er A	SMEDL-01		 Tissue	e/ cell line/ etc	. F1 EDL - (Cytosolic Frac	tion				
Gel type	8	10%		Electro	ophoresis Volt	age 124		Trar	nsfer Voltage	25		
Protien Load	per Well	50 ug		 Durati	on	01:3	0 hrs	12	Duration	Duration 45minutes		
Primary A	ntiboo	ły					Secor	ndary A	ntibody			
Name (Do No	t Abbrevi	ate) phosph	o Protein kir	nase- B- 473			Name	Anti-Ra	abbit			
Dilution 1:10	000	1	Mediu	ım 5% BSA	A in TBST		Dilution	1:1000	м	edium 5%	Wilk in TBST	
Incubation tir	ne Ove	rnight		a.			Incubat	ion time	One hour	5		
Lane #1	Lane # 2	Lane # 3	Lane # 4	Lane # 5	Lane # 6	Lane # 7	Lane # 8	Lane # 9	Lane # 10	Lane # 11	Lane # 12	
BL	MW	6m Male	30m Male	36m Male	Sample Buffer	6m Female	26m Female	30m Female	Positive Control	Sample Buffer	Sample Buffer	
		Plac	e Scan of F	E D L Me 6 3	-(5) 10.36 	F. 6 	emelis 26 3 3 050 Pat	30'		Exposure f	Vieght	
Location of So	an	\\Blough	n-raid\exp-da	ata\Project f	older\Aging &	aortic stiff	ness\FILMS\E	EDL\p-Akt-	473			
Location of Ex	cel Data	\\Blough	n-raid\exp-da	ata\Project f	older\Aging &	aortic stiff	ness\Excel\El	DL\p-Akt-4	173			
Notes												
_									e	email Repor	t	
Signature	e											

Laboratory of Molecular Physiology, Marshall University, Science Bldg. Suite 311, 1 John Marshall Drive, Huntington, WV, 25755 * Phone: 304-696-3267 Fax: 304-696-7136 http://www.science.marshall.edu/blough

	6m male	30m male	36m male	6m female	26m female	30m female
	1.02	0.77	1.13	1.10	1.62	0.79
	0.90	0.71	0.99	1.08	2.27	0.78
	1.03	1.10	1.58	0.73	1.08	0.68
	1.02	1.17	1.60	0.68	1.00	0.73
	0.98	0.84	1.18	0.63	1.61	0.91
	1.22	0.92	1.48	0.69	0.78	0.89
Ν	6	6	6	6	6	6
Mean	1.03	0.92	1.33	0.82	1.39	0.80
SD	0.11	0.18	0.26	0.21	0.55	0.09
SEM	0.05	0.08	0.12	0.09	0.24	0.04

Two Way Analysis of Variance

Comparisons for	factor: SEX with	in 6			
Comparison	Diff of Means	р	q	Р	P<0.05
M vs. F	0.210	2	$1.\bar{8}45$	0.202	No
Comparisons for	factor: SEX with	in 3	0		
Comparison	Diff of Means	р	q	Р	P<0.05
F vs. M	0.478	2	4.206	0.006	Yes
Comparisons for		in 3	6		
Comparison		р	q	Р	P<0.05
M vs. F	0.528	2	4.646	0.003	Yes
		• •			
Comparisons for					D 0 0 Z
Comparison	Diff of Means	р	q	Р	P<0.05
Comparison 36.000 vs. 30.000	Diff of Means 0.409	р 3	q 3.601	0.042	Yes
Comparison	Diff of Means 0.409	р 3 2	q 3.601		Yes
Comparison 36.000 vs. 30.000	Diff of Means 0.409	р 3	q 3.601	0.042	Yes
Comparison 36.000 vs. 30.000 36.000 vs. 6.000	Diff of Means 0.409 0.298	р 3 2	q 3.601 2.621	0.042 0.074	Yes No
Comparison 36.000 vs. 30.000 36.000 vs. 6.000 6.000 vs. 30.000	Diff of Means 0 0.409 0.298 0.111	p 3 2 2	q 3.601 2.621 0.980	0.042 0.074	Yes No
Comparison 36.000 vs. 30.000 36.000 vs. 6.000 6.000 vs. 30.000 Comparisons for	Diff of Means 0 0.409 0.298 0.111 factor: AGE wit	p 3 2 2	q 3.601 2.621 0.980	0.042 0.074	Yes No No
Comparison 36.000 vs. 30.000 36.000 vs. 6.000 6.000 vs. 30.000 Comparisons for Comparison	Diff of Means 0 0.409 0.298 0.111 factor: AGE with Diff of Means	p 3 2 2 hin F	q 3.601 2.621 0.980	0.042 0.074 0.494 P	Yes No No P<0.05
Comparison 36.000 vs. 30.000 36.000 vs. 6.000 6.000 vs. 30.000 Comparisons for	Diff of Means 0 0.409 0.298 0.111 factor: AGE with Diff of Means 0 0.596	p 3 2 2 hin F 3	q 3.601 2.621 0.980	0.042 0.074 0.494	Yes No No
Comparison 36.000 vs. 30.000 36.000 vs. 6.000 6.000 vs. 30.000 Comparisons for Comparison	Diff of Means 0 0.409 0.298 0.111 factor: AGE with Diff of Means 0 0.596	p 3 2 2 hin F	q 3.601 2.621 0.980	0.042 0.074 0.494 P	Yes No No P<0.05

										Prir	and the state and the	
Date	20	08/08/18		Projec	t	Aging an	d Aortic Stiffr	ness				
Report Num	iber AS	MEDL-01		Tissue	e/ cell line/ et	c. F1 EDL - (Cytosolic Frac	ction				
Gel type		10%		Electro	ophoresis Vo	ltage 124		Tran	isfer Voltage	25		
Protien Load	d per Well	50 ug		 Durati	on	01:3	30 hrs		Duration 45minutes			
Primarv	Antibod	v				·	Secor	ndarv A	ntibody			
5			alian target o	of rapamycii	n(mTOR)		Name	Anti-Ra	37.0			
	1000 (p-PTE	1	Mediu		A in TBST		 Dilution	1:1000	M	edium 5% N	Ailk in TBST	
Incubation time Overnight						Incubat	ion time	1:00 hr				
Lane #1	Lane # 2	Lane # 3	Lane # 4	Lane # 5	Lane # 6	Lane # 7	Lane # 8	Lane # 9	Lane # 10	Lane # 11	Lane # 12	
BL	MW	6m Male	30m Male	36m Male	Sample Buffer	6m Female	26m Female	30m Female	Sample Buffer	Positive Control	Sample Buffer	
					here a	males				moleculary	Vieght	
		Plac	۲ ۱°(۲°(۲°(۲°(۲°) ۲°(۲°) ۲°) ۲°) ۲°)		- X - 1 m TO Ant: 0 08 R	Rabbit	3		Ā	61 Vused Fo	_	
ocation of	Scan		ce Scan of F	ilm Here		***	3 iness\FILMS\E	EDL\Calcine		61	_	
Location of		\\Blough	ce Scan of F n-raid\exp-da	ilm Here ata∖Project f	older\Aging	& aortic stiff	ness\FILMS\E iness\EXCEL\I			61	_	
		\\Blough	ce Scan of F n-raid\exp-da	ilm Here ata∖Project f	older\Aging	& aortic stiff	60 W			61	_	
Location of I		\\Blough	ce Scan of F n-raid\exp-da	ilm Here ata∖Project f	older\Aging	& aortic stiff	60 W		eurin	61	or Analysis	

	6m male	30m male	36m male	6m female	26m female	30m female
	13.00	19.30	23.50	17.20	13.00	13.90
	13.30	19.10	23.10	17.30	13.30	13.80
	13.15	19.20	23.30	17.25	13.15	13.85
	7.00	21.40	33.00	15.80	8.40	14.40
	6.80	21.50	33.30	15.50	8.70	14.20
	6.90	21.45	33.15	15.65	8.55	14.30
N	6	6	6	6	6	6
Mean	10.03	20.33	28.23	16.45	10.85	14.08
SD	3.43	1.23	5.40	0.88	2.52	0.26
SEM	1.53	0.55	2.41	0.39	1.13	0.11

Two Way Analysis of Variance

Comparisons for f	factor: Age with	in M			
Comparison	•	р	q	Р	P<0.05
36.000 vs. 6.000	23.232	3	17.817	< 0.001	Yes
36.000 vs. 30.000	9.922	2	7.609	< 0.001	Yes
30.000 vs. 6.000	13.310	2	10.208	< 0.001	Yes
Comparisons for f	Castor A go with	n F			
Comparisons for f	•		~	р	D <0.05
Comparison	Diff of Means	p	q 5.751	P	P<0.05
6.000 vs. 30.000	7.499	3	5.751		Yes
6.000 vs. 36.000	6.009	2	4.609		Yes
36.000 vs. 30.000	1.489	2	1.142	0.426	No
Comparisons for f	factor: Sex withi Diff of Means	n 6 p	a	Р	P<0.05
F vs. M	8.037	р 2	q 6.164	<0.001	Yes
Comparisons for f				<0.001	105
Comparison				Р	P<0.05
M vs. F	12.772	р 2	q 9.795	▲ <0.001	Yes
WI VS. F	12.772	Z	9.795	<0.001	1 es
Comparisons for f	factor: Sex withi	n 36			
Comparison	Diff of Means	р	q	Р	P<0.05
M vs. F	21.205	2	16.262	< 0.001	Yes

Experiment	er Sat	tyanarayana	Paturi							Prir	it Form
Date	20	08/08/18		Projec	t	Aging an	d Aortic Stiff	fness			
Report Num	nber AS	MEDL-01		Tissue	/ cell line/ et	tc. F1 EDL - (Eytosolic Fra	iction			
Gel type		10%		Electro	ophoresis Vo	ltage 124		Tran	isfer Voltage	25	
Protien Loa	d per Well	50 ug		Durati	Duration 01 : 30 hrs			Duration			
Primary	Antibod	у					Seco	ndary A	ntibody		
	lot Abbrevia		o mammalia	an target of	rapamycin (µ	o-mTOR)	Name	Anti-Ra	17.0		
Dilution 1:1000 (p-PTEN) Medium				ım 5% BSA	A in TBST		 Dilutio	n 1:500	Me	edium 5% N	Ailk in TBST
Incubation	time Over	night					Incuba	tion time	1:00 hr	<u>.</u>	
Lane #1	Lane # 2	Lane # 3	Lane # 4	Lane # 5	Lane # 6	Lane # 7	Lane # 8	Lane # 9	Lane # 10	Lane # 11	Lane # 12
BL	MW	6m Male	30m Male	36m Male	Sample Buffer	6m Female	26m Female	30m Female	Sample Buffer	Positive Control	Sample Buffer
		Plac	the Scan of H		-	6 26 3 De - 18 De - 18 mt: Rat fatu	1		ŀ	1.5 ' Molecular V 61	
Location of	Scan	\\Blough	n-raid\exp-da	ata\Project f	older\Aging	& aortic stiff	ness\FILMS\	EDL\p-mTC	PR		
Location of	Excel Data	\\Blough	n-raid\exp-da	ata\Project f	older\Aging	& aortic stiff	ness\EXCEL`	\EDL			
Notes										mail Report	
										man neport	
Signatu		ar Physiology A	arshall Universi	ity Science Ride	1 Suite 211 1 L	nhn Marchall Dri	ve Huntington	W/V 25755 * D	hone: 304-696-3	267 Fax- 204 40	6-7136

Laboratory of Molecular Physiology, Marshall University, Science Bldg. Suite 311, 1 John Marshall Drive, Huntington, WV, 25755 * Phone: 304-696-3267 Fax: 304-696-7136 http://www.science.marshall.edu/blough

	6m male	30m male	36m male	6m female	26m female	30m female
	1.30	0.73	0.72	1.31	1.30	0.91
	1.27	0.73	0.73	1.35	1.23	0.93
	1.29	0.73	0.73	1.33	1.26	0.92
	2.80	0.50	0.45	1.14	2.00	1.39
	2.85	0.52	0.45	1.15	1.95	1.39
	2.60	0.60	0.49	1.34	1.96	1.09
Ν	6	6	6	6	6	6
Mean	2.02	0.64	0.59	1.27	1.62	1.11
SD	0.81	0.11	0.15	0.10	0.39	0.23
SEM	0.36	0.05	0.07	0.04	0.17	0.10

Two Way Analysis of Variance

-	actor: SEX with Diff of Means 0.751	in 6 p 2	q 4.751	P 0.002	P<0.05 Yes						
Comparisons for factor: SEX within 30											
Comparison F vs. M	Diff of Means 0.980	р 2	q 6.202	P <0.001	P<0.05 Yes						
F VS. M	0.980	Ζ	0.202	<0.001	res						
Comparisons for f	actor: SEX with	in 3	6								
Comparison		р	q	Р	P<0.05						
F vs. M	0.513	2	3.249	0.029	Yes						
			Л								
6.000 vs. 36.000	Diff of Means 1.425	р 3	q 9.022	P <0.001 <0.001	P<0.05 Yes Ves						
Comparison	Diff of Means 1.425 1.382	р 3 2	q								

Experiment	er	Satyanarayana	rucun							Prir	
Date		2008/04/14		Projec	t	Aging and	d Aortic Stiffr	ness			
Report Num	nber _	ASMEDL-01		Tissue	e/ cell line/ et	c. F1 EDL - C	Sytosolic Frac	tion			
Gel type		10%		Electro	ophoresis Vol	ltage 124		Tran	sfer Voltage	25	
protien Load	d per Well	50 ug		 Durati	Duration 01:30 hrs Du					Duration 45minutes	
Primary	Antibo	odv				<u>b</u>	Secor	ndary Ai	ntibody		
540		viate) Ribosor	mal protein S	56 kinase (p7	70S6K)		Name	Anti-Ral	1.		
Dilution 1:1000 Medium			e federal antipation	5% BSA in TBST					Aedium 5% Milk in TBST		
ncubation 1	time Ov	/ernight		ē1			Incubat	ion time	One hour	6	
Lane #1	Lane # 2	2 Lane # 3	Lane # 4	Lane # 5	Lane # 6	Lane # 7	Lane # 8	Lane # 9	Lane # 10	Lane # 11	Lane # 12
BL	MW	6m Male	30m Male	36m Male	Sample Buffer	бт Female	26m Female	30m Female	Positive Control	Sample Buffer	Sample Buffer
		-		Fale 6 30	9-01 8-36	Femal 6 26.	30			5 Minute	
			te Scan of F	6 30 1°(1:10 06 .	36 000) P7 000) An 30/200	6 26. 0.56k ti Rab 8 F	30°			5 Minute Molecular V 70 Used Fo	
ocation of	Scan		te Scan of F	6 30 1°(1:10 06 .	36 '	6 26. 0.56k ti Rab 8 F	30°	:DL\p70s6k		Molecular V 70	
		\\Blough	te Scan of F	6 30 1° (1 : 10 0 6 . Film Here ata\Project fo	36 000) P7 000) An 30/200	6 26 . 0.56 k t Rab 8 f	30 bit 2 tuii ness\FILMS\E			Molecular V 70	
ocation of ocation of Notes		\\Blough	te Scan of F	6 30 1° (1 : 10 0 6 . Film Here ata\Project fo	36 000) P 7 000) Am 30 200 01der\Aging	6 26 . 0.56 k t Rab 8 f	30 bit 2 tuii ness\FILMS\E			Molecular V 70	
ocation of		\\Blough	te Scan of F	6 30 1° (1 : 10 0 6 . Film Here ata\Project fo	36 000) P 7 000) Am 30 200 01der\Aging	6 26 . 0.56 k t Rab 8 f	30 bit 2 tuii ness\FILMS\E			Molecular V 70	r Analysis

http://www.science.marshall.edu/blough

	6m male	30m male	36m male	6m female	26m female	30m female
	8.9	22.5	12.4	8.9	14.2	33.1
	7.8	23.3	12.1	8.3	14.1	34.5
	13.5	21.7	13.9	14.2	14.9	21.7
	13.8	21.1	14.2	14.2	15	21.5
	8.35	22.9	12.25	8.6	14.15	33.8
	13.65	21.4	14.05	14.2	14.95	21.6
Ν	6	6	6	6	6	6
Mean	11.00	22.15	13.15	11.40	14.55	27.70
SD	2.93	0.88	0.99	3.07	0.44	6.70
SEM	1.31	0.39	0.44	1.37	0.20	3.00

Two Way Analysis of Variance

Comparisons for factor: Age within M										
Comparison	Diff of Means	р	q	Р	P<0.05					
30.000 vs. 36.000	7.383	3	3.686	0.037	Yes					
30.000 vs. 6.000	5.167	2	2.579	0.078	No					
6.000 vs. 36.000	2.217	2	1.107	0.440	No					
Comparisons for factor: Age within F										
Comparison	Diff of Means	р	q	Р	P<0.05					
36.000 vs. 6.000	16.917	3	8.445	< 0.001	Yes					
36.000 vs. 30.000	11.633	2	5.808	< 0.001	Yes					
30.000 vs. 6.000	5.283	2	2.638	0.072	No					
Comparisons for f Comparison M vs. F	actor: Sex withi Diff of Means 0.267	n 6 p 2	q 0.133	P 0.926	P<0.05 No					
Comparisons for f Comparison M vs. F	actor: Sex withi Diff of Means 0.150	n 30 p 2	q 0.0749	P 0.958	P<0.05 No					
Comparisons for f Comparison F vs. M	actor: Sex withi Diff of Means 18.867	n 36 p 2	q 9.419	P <0.001	P<0.05 Yes					

Date	200	8/05/08		Projec	t	Aging and	d Aortic Stiffn	ess				
Report Number	ASM	MEDL-01		Tissue	e/ cell line/ etc	. F1 EDL - C	ytosolic Fract	tion				
Gel type	1	0%		Electro	ophoresis Vol	tage 124		Transfer Voltage 25				
Protien Load per	rWell 5	0 ug		 Durati	Duration 01:30 hrs				Duration 45minutes			
Primary An	tibody	,		<u></u>		n	Secon	dary A	ntibody			
Name (Do Not Abbreviate) phospho-Ribosomal p				protein S6	Secondary Antik DteinS6 kinase (p-p70S6K389) Name Anti-Rabbit			100				
Dilution 1:1000 Medium			entertexter and there are	A in TBST		 Dilution			edium 5% N	/ilk in TBST		
Incubation time	Overn	night					Incubati	on time	One hour	6		
Lane #1 Lar	ne # 2	Lane # 3	Lane # 4	Lane # 5	Lane # 6	Lane # 7	Lane # 8	Lane # 9	Lane # 10	Lane # 11	Lane # 12	
BL N	MW	6m Male	30m Male	36m Male	Sample Buffer	6m Female	26m Female	30m Female	Positive Control	Sample Buffer	Sample Buffer	
				Mal s &	-EDI	Fem	B	2	*	Exposure t 3 Minute	Ime	
		Plac		o (1:2 (1:2 10]30]	500) p 500) p 500) A [2008	1 6	S.	(389) k			Vieght	
Location of Scan	1		te Scan of F	۵ (۱:4 ۱۵)30 ۱۱۳ Here	36	-Pte	B S6KC abbi			3 Minute Molecular V 70	Vieght	
Location of Scan		\\Blough	e Scan of F p-raid\exp-da	۲ ۲ ۲ ۲ ۲ ۲ ۲ ۲ ۲ ۲ ۲ ۲ ۲ ۲ ۲ ۲ ۲ ۲ ۲	500) p 500) A [2008	-P#c	S6k(abbi atus	DL\phosp	ho p70s6k38	3 Minute Molecular V 70	Vieght	
		\\Blough	e Scan of F p-raid\exp-da	۲ ۲ ۲ ۲ ۲ ۲ ۲ ۲ ۲ ۲ ۲ ۲ ۲ ۲ ۲ ۲ ۲ ۲ ۲	8 500) p 500) A J2008	-P#c	S6k(abbi atus	DL\phosp	ho p70s6k38	3 Minute Molecular V 70	Vieght	

Laboratory of Molecular Physiology, Marshall University, Science Bldg. Suite 311, 1 John Marshall Drive, Huntington, WV, 25755 * Phone: 304-696-3267 Fax: 304-696-7136 http://www.science.marshall.edu/blough

	6m male	30m male	36m male	6m female	26m female	30m female
	2.85	0.87	0.53	0.99	1.62	0.50
	3.25	0.84	0.54	1.06	1.63	0.48
	2.26	1.31	0.54	0.65	1.08	0.38
	2.20	1.35	0.54	0.64	1.08	0.38
	3.34	1.05	0.58	1.05	1.39	0.37
	1.86	0.91	0.47	0.62	1.54	0.77
Ν	6	6	6	6	6	6
Mean	2.63	1.05	0.53	0.84	1.39	0.48
SD	0.61	0.22	0.04	0.22	0.26	0.15
SEM	0.27	0.10	0.02	0.10	0.11	0.07

Two Way Analysis of Variance

Comparisons for	factor: SEX with	in 6			
Comparison	Diff of Means	р	q	Р	P<0.05
M vs. F	1.793	2	14.364	< 0.001	Yes
Comparisons for a Comparison F vs. M		in 3 p 2	q	P 0.065	P<0.05 No
Comparisons for a Comparison M vs. F		in 3 p 2	6 q 0.414	P 0.772	P<0.05 No
Comparisons for		hin N	М		
Comparison		р	q	Р	P<0.05
6.000 vs. 36.000				< 0.001	Yes
6.000 vs. 30.000	1.575			< 0.001	Yes
30.000 vs. 36.000	0.519	2	4.157	0.006	Yes
Comparisons for					D 0 0 5
Comparison		p	q	P	P<0.05
30.000 vs. 36.000	0.909	3	7.282	< 0.001	Yes

0.556

0.353

2

2

4.453

2.828

0.004

0.055

Yes

No

30.000 vs. 6.000

6.000 vs. 36.000

Date		Paturi							PIII	nt Form
	2008/08/18		Projec	t	Aging an	d Aortic Stiffr	ness			
Report Number	ASMEDL-01		Tissue	e/ cell line/ et	c. F1 EDL - 0	Cytosolic Frac	tion			
Gel type	10%		Electro	ophoresis Vo	ltage 124		Trar	nsfer Voltage	25	
Protien Load per W	/ell 50 ug		— Durati	ion	01:3	0 hrs		Duration	ation 45minutes	
Primary Antik	oody					Secor	ndary A	ntibody		
Name (Do Not Abb	100	urin A (CnA)				Name	Anti-Ra	bbit		
Dilution 1:1000	12	Mediur	m 5% BS/	A in TBST		 Dilutior	1:1000	м	edium 5% l	Wilk in TBS1
ncubation time	Overnight		a.	Incubation time 1:00 h			1:00 hr	8.		
Lane #1 Lane	#2 Lane#3	Lane # 4	Lane # 5	Lane # 6	Lane # 7	Lane # 8	Lane # 9	Lane # 10	Lane # 11	Lane # 12
				Sample	6m	26m	30m	Sample	Positive	Sample
BL MV	V 6m Male	30m Male	36m Male	Buffer	Female	Female	Female	Buffer	Control	Buffer
	- *	-	6. 3	0 36	6 26	30	2		Molecular \	Vieght
	Plac	re Scan of F	1. 1.	000) Ca 1000) A 17/200	teiner Inti M 8 Fe	30		ī	Molecular V 61 Used Fc	
ocation of Scan		re Scan of F	ilm Here		4	*			61	
	\\Blough		ilm Here ta\Project f	older\Aging	& aortic stiff	ness\FILMS\F	EDL\Calcin		61	
ocation of Excel D	\\Blough	n-raid\exp-da	ilm Here ta\Project f	older\Aging	& aortic stiff	ness\FILMS\F	EDL\Calcin		61	
Location of Scan Location of Excel D Notes	\\Blough	n-raid\exp-da	ilm Here ta\Project f	older\Aging	& aortic stiff	ness\FILMS\F	EDL\Calcin		61	

Laboratory of Molecular Physiology, Marshall University, Science Bldg. Suite 311, 1 John Marshall Drive, Huntington, WV, 25755 * Phone: 304-696-3267 Fax: 304-696-7136 http://www.science.marshall.edu/blough

	6m male	30m male	36m male	6m female	26m female	30m female
	8.40	22.60	24.20	8.20	15.50	21.20
	7.90	22.70	24.60	7.90	15.60	21.30
	9.00	17.50	22.60	9.70	15.90	25.30
	9.00	17.50	22.60	9.70	16.00	25.20
	7.10	19.50	26.60	7.40	16.10	23.20
	6.80	19.30	26.40	7.40	16.90	23.20
Ν	6	6	6	6	6	6
Mean	8.03	19.85	24.50	8.38	16.00	23.23
SD	0.94	2.33	1.75	1.06	0.50	1.79
SEM	0.42	1.04	0.78	0.48	0.22	0.80

Two Way Analysis of Variance

Comparisons for factor: Age within M

Comparison	Diff of Means	р	q	Р	P<0.05
36.000 vs. 6.000	16.467	3	26.438	< 0.001	Yes
36.000 vs. 30.000	4.650	2	7.466	< 0.001	Yes
30.000 vs. 6.000	11.817	2	18.972	< 0.001	Yes

Comparisons for f	actor: Age withi	in F			
Comparison	Diff of Means	р	q	Р	P<0.05
36.000 vs. 6.000	14.850	3	23.842	< 0.001	Yes
36.000 vs. 30.000	7.233	2	11.613	< 0.001	Yes
30.000 vs. 6.000	7.617	2	12.229	< 0.001	Yes

Comparisons for factor: Sex within 6									
Comparison	Diff of Means	р	q	Р	P<0.05				
F vs. M	0.350	2	0.562	0.694	No				

Comparisons for factor: Sex within 30									
Comparison	Diff of Means	р	q	Р	P<0.05				
M vs. F	3.850	2	6.181	< 0.001	Yes				

Comparisons for factor: Sex within 36									
Comparison	Diff of Means	р	q	Р	P<0.05				
M vs. F	1.267	2	2.034	0.161	No				

DIAPHRAGM

Date Report Number Sel type Protien Load per W Primary Antik Name (Do Not Abb	2008/04/24 ASMEDL-01 10%		Projec	t e∕ cell line∕ et		d Aortic Stiff RAGM - Cyto		n			
Sel type Protien Load per W Primary Antik	10%		Tissue	e/ cell line/ et	c. F1 DIAPH	RAGM - Cyto	osolic Fractio	n			
Protien Load per W Primary Antik	14-259/ SH2		Electrophoresis Voltage 124 Transfer V					511			
Primary Antib	50		Electro	ophoresis Vo	ltage 124		Trans	sfer Voltage	25		
-	ell 50 ug		 Durati	on	01:3	0 hrs		Duration	45minute	s	
-	oody					Seco	ndary Ar	ntibody			
AULIE (DO NOL ADD	reviate) Protein	kinase - B (A	KT)			Name	Anti Rab	bit			
Dilution 1:1000		Mediu	m 5% BS/	A in TBST		Dilution	n 1:1000	Me	edium 5% M	Ailk in TBST	
ncubation time	Overnight		~			Incubat	tion time	1 : 00hr	6		
Lane #1 Lane ;	# 2 Lane # 3	Lane # 4	Lane # 5	Lane # 6	Lane # 7	Lane # 8	Lane # 9	Lane # 10	Lane # 11	Lane # 12	
BL MW	6m Male	30m Male	36m Male	Sample Buffer	6m Female	26m Female	30m Female	Sample Buffer	Positive Control	Sample Buffer	
	Plac	Ξ.	1°(1: 2°(1: 08/	16 - 1 1000) 1000) 27/200	62	6 30'	53 • <	Ī	5 sec Molecular V 60 Used Fo		
ocation of Scan	\\Blough	n-raid\exp-da	ta\Project f	older\Aging	& aortic stiff	ness\FILMS\	DIAPHRAGN	∕I∖AKT			
ocation of Excel D	ata \\Blough	n-raid\exp-da	ta\Project f	older\Aging	& aortic stiff	ness\Excel\D	DIAPHRAGM				
Notes											
								e	mail Report	L.	

http://www.science.marshall.edu/blough

	6m male	30m male	36m male	6m female	26m female	30m female
	14.4	15.7	19.2	16	18.2	16.5
	14.3	15.9	19.2	15.9	18.1	16.5
	13.6	15.5	20.6	15.1	17.7	17.5
	13.6	15.6	20.7	14.9	17.7	17.5
	14.2	17.8	17.9	17.3	17.1	15.8
	14	17.8	17.9	17.1	17.3	15.8
Ν	6	6	6	6	6	6
Mean	14.02	16.38	19.25	16.05	17.68	16.60
SD	0.35	1.11	1.23	0.99	0.43	0.76
SEM	0.16	0.49	0.55	0.44	0.19	0.34

Two Way Analysis of Variance

Comparisons for f	actor: Age with	in M									
Comparison	Diff of Means	р	q	Р	P<0.05						
36.000 vs. 6.000	5.233	3	14.623	< 0.001	Yes						
36.000 vs. 30.000	2.867	2	8.010	< 0.001	Yes						
30.000 vs. 6.000	2.367	2	6.613	< 0.001	Yes						
Comparisons for f	actor: Age with	in F									
Comparisons for factor: Age within F Comparison Diff of Means p q P P<0.05											
30.000 vs. 6.000	1.633	р 3	ч 4.564	-	Yes						
30.000 vs. 36.000		$\frac{3}{2}$	3.027	0.000	Yes						
36.000 vs. 6.000	0.550	$\frac{2}{2}$	1.537	0.286	No						
Comparisons for f	actor: Sex withi	n 6									
Comparison	Diff of Means	p	q	Р	P<0.05						
F vs. M	2.033	р 2	ч 5.681	<0.001	Yes						
1 V.S. 1VI	2.055	2	5.001	<0.001	103						
Comparisons for f	actor: Sex withi	n 30									
Comparison	Diff of Means	р	q	Р	P<0.05						
F vs. M	1.300	2	3.632	0.016	Yes						
Comparisons for f	Costor Soy withi	n 26									
Comparisons for f	Diff of Means		a	Р	P<0.05						
M vs. F	2.650	р 2	q 7.405	P <0.001	Yes						

Date Report Number Gel type	2008/04/24								Prir			
Gel type			Projec	t	Aging an	nd Aortic Stiffi	ness					
10.200	ASMEDL-01		Tissue	e/ cell line/ e	tc. F1 DIAPH	HRAGM - Cyto	solic Fracti	on				
1000	10%		Electro	ophoresis Va	oltage 124		Tran	sfer Voltage	25			
Protien Load per We	50 ug		 Durati	-	100 J	30 hrs		Duration		5		
44			<u></u>		5 <u>.</u>	Saca	ndary A	- atibody				
Primary Antibe Name (Do Not Abbre	38.5	o protoin Kir	naco-R-308 (- AKT-308)		Name	Anti-Ra	17.0				
Dilution 1:500		Mediu	e terrete antisecco	A in TBST		 Dilution	2		Medium 5% Milk in TBST			
	vernight						1 1	1:00hr				
Lane #1 Lane #	2 Lane#3	Lane # 4	Lane # 5	Lane # 6	Lane # 7	Lane # 8	Lane # 9	Lane # 10	Lane # 11	Lane # 1		
						26m	30m			T		
BL MW	6m Male	30m Male	36m Male	Sample Buffer	6m Female	Female	Female	Sample Buffer	Positive Control	Sample Buffer		
						700	*		Molecular V 60	Vieght		
			°():5 2°(1:55	100) p. 100) A1 06 J201	- Akt At: Ra 13008	308 Boit: Patin	*			Vieght		
	Plac	ce Scan of F	?'(!: 5	100) p 100) A 100) A 100 [20]	- Akt - ht: Ra 2008	308 Abit: Patur	*		60			
Location of Scan		ce Scan of F n-raid∖exp-da	ilm Here	00) A 06 [20]	nt: Ra 12008	30 8 Boit: Protection fness\FILMS\I	DIAPHRAG		60			
Location of Scan	\\Blough	n-raid\exp-da	ilm Here	ico) A o6 [20] iolder\Aging	& aortic stiff	Patur		И\p-Akt-308	60			
	\\Blough	n-raid\exp-da	ilm Here	ico) A o6 [20] iolder\Aging	& aortic stiff	fness\FILMS\I		И\p-Akt-308	60			
	\\Blough	n-raid\exp-da	ilm Here	ico) A o6 [20] iolder\Aging	& aortic stiff	fness\FILMS\I		/√p-Akt-308	60			

Laboratory of Molecular Physiology, Marshall University, Science Bldg. Suite 311, 1 John Marshall Drive, Huntington, WV, 25755 * Phone: 304-696-3267 Fax: 304-696-7136 http://www.science.marshall.edu/blough

	6m male	30m male	36m male	6m female	26m female	30m female
	1.66	2.20	3.76	0.82	0.71	0.43
	1.76	2.19	3.74	0.88	0.73	0.43
	0.78	0.97	1.07	1.42	1.45	0.79
	0.77	0.98	1.05	1.38	1.47	0.79
	1.29	2.00	1.23	0.74	1.15	0.62
	1.25	2.15	1.29	0.83	0.97	0.65
Ν	6	6	6	6	6	6
Mean	1.25	1.75	2.02	1.01	1.08	0.62
STDEV	0.42	0.60	1.34	0.30	0.34	0.16
SEM	0.19	0.27	0.60	0.14	0.15	0.07

Two Way Analysis of Variance

Comparisons for fac	tor: SEX with	in 6			
Comparison D	iff of Means	р	q	Р	P<0.05
M vs. F	0.238	2	0.891	0.534	No
Comparisons for fac		in 3	0		
-	oiff of Means	р	q	Р	P<0.05
M vs. F	0.668	2	2.500	0.087	No
Comparisons for fac Comparison D M vs. F	tor: SEX with i ff of Means 1.405	in 3 p 2	6 q 5.257	P <0.001	P<0.05 Yes
Comparisons for fac				D	D-0 05
Comparison D	oiff of Means	р	q	P 0.120	P<0.05
Comparison D 36.000 vs. 6.000 D	iff of Means 0.772	р 3	q 2.888	0.120	No
Comparison D	iff of Means 0.772	р	q	0.120 0.476 I	
Comparison D 36.000 vs. 6.000 36.000 vs. 30.000 30.000 vs. 6.000 30.000 vs. 6.000	iff of Means 0.772 0.273 0.499 tor: AGE wit l	p 3 2 2	q 2.888 1.021 1.867	0.120 0.476 I	No Do Not Test Do Not Test
Comparison D 36.000 vs. 6.000 36.000 36.000 vs. 30.000 30.000 30.000 vs. 6.000 Comparisons for faction for	iff of Means 0.772 0.273 0.499	p 3 2 2 nin F	q 2.888 1.021 1.867	0.120 0.476 I	No Do Not Test
Comparison D 36.000 vs. 6.000 36.000 vs. 30.000 30.000 vs. 6.000 30.000 vs. 6.000 Comparisons for fact D Comparison D 30.000 vs. 36.000 30.000 vs. 36.000	iff of Means 0.772 0.273 0.499 tor: AGE wit l	p 3 2 2 nin H 3	q 2.888 1.021 1.867	0.120 0.476 I 0.197 I	No Do Not Test Do Not Test
Comparison D 36.000 vs. 6.000 36.000 36.000 vs. 30.000 30.000 30.000 vs. 6.000 Comparisons for faction for	iff of Means 0.772 0.273 0.499 tor: AGE with	p 3 2 2 nin H 3	q 2.888 1.021 1.867	0.120 0.476 I 0.197 I P 0.447 0.857 I	No Do Not Test Do Not Test P<0.05

Experiment	er S	atyanarayana	Paturi							Prir	nt Form	
Date	2	008/04/24		Projec	t	Aging ar	d Aortic Stiff	ness				
Report Num	nber A	ASMEDL-01 10%		Tissue	Tissue/ cell line/ etc. F1 DIAPHR			APHRAGM - Cytosolic Fraction				
Gel type				Electro	Electrophoresis Voltage 124		Trans		nsfer Voltage	25		
Protien Load	d per Well	50 ug		Duratio	on	01:3	30 hrs		Duration	45minute	s	
Primary	Antibo	dy					Seco	ndary A	ntibody			
Name (Do N	lot Abbrev	iate) phosph	io - Protein k	inase - B (p-,	AKt-473)		Name	Anti-Ra	bbit			
Dilution 1	:1000		Mediu	ım 5% BSA	5% BSA in TBST			Dilution 1:2500		00 Medium 5% Milk in TBST		
Incubation 1	time Ove	ernight		-			Incuba	tion time	1:00hr	6		
Lane #1	Lane # 2	Lane # 3	Lane # 4	Lane # 5	Lane # 6	Lane # 7	Lane # 8	Lane # 9	Lane # 10	Lane # 11	Lane # 12	
BL	MW	6m Male	30m Male	36m Male	Sample Buffer	6m Female	26m Female	30m Female	Sample Buffer	Positive Control	Sample Buffer	
	1		I I	I []			~ ~	1		1	1	



Laboratory of Molecular Physiology, Marshall University, Science Bldg. Suite 311, 1 John Marshall Drive, Huntington, WV, 25755 * Phone: 304-696-3267 Fax: 304-696-7136 http://www.science.marshall.edu/blough

	6m male	30m male	36m male	6m female	26m female	30m female
	1.00	1.00	1.00	1.00	1.00	1.00
	1.00	1.00	1.00	1.00	1.00	1.00
	0.48	0.35	0.30	2.53	1.87	1.55
	0.71	0.52	0.41	1.80	1.82	1.41
	1.25	1.88	0.69	0.82	0.96	0.98
	0.84	1.15	0.41	1.15	1.14	1.14
Ν	6	6	6	6	6	6
Mean	0.88	0.98	0.64	1.38	1.30	1.18
SD	0.26	0.54	0.31	0.66	0.43	0.24
SEM	0.12	0.24	0.14	0.29	0.19	0.11

Two Way Analysis of Variance

Comparisons for fa	actor: SEX with	in 6			
Comparison	Diff of Means	р	q	Р	P<0.05
F vs. M	0.502	2	2.836	0.054	No
Comparisons for fa	actor: SFX with	in 3	Λ		
-				Р	P<0.05
-	Diff of Means	p	q		
F vs. M	0.316	2	1.784	0.217	No
Comparisons for fa	actor: SEX with	in 3	6		
Comparison	Diff of Means	р	q	Р	P<0.05
F vs. M	0.545	2	3.075	0.038	Yes
Comparisons for fa		nin N	М		
Comparison		nin N P	M q	Р	P<0.05
-		р 3	q	P 0.366	P<0.05 No
Comparison	Diff of Means 0.345	р	q	0.366	
Comparison 30.000 vs. 36.000	Diff of Means 0.345	р 3	q 1.946	0.366 0.690 I	No
Comparison 30.000 vs. 36.000 30.000 vs. 6.000 6.000 vs. 36.000	Diff of Means 0.345 0.101 0.244	p 3 2 2	q 1.946 0.569 1.377	0.366 0.690 I	No Do Not Test
Comparison 30.000 vs. 36.000 30.000 vs. 6.000 6.000 vs. 36.000 Comparisons for fa	Diff of Means 0.345 0.101 0.244 actor: AGE witl	p 3 2 2	q 1.946 0.569 1.377	0.366 0.690 I 0.338 I	No Do Not Test Do Not Test
Comparison 30.000 vs. 36.000 30.000 vs. 6.000 6.000 vs. 36.000 Comparisons for fa Comparison	Diff of Means 0.345 0.101 0.244 actor: AGE with Diff of Means	p 3 2 2 nin F	q 1.946 0.569 1.377	0.366 0.690 I 0.338 I	No Do Not Test Do Not Test P<0.05
Comparison 30.000 vs. 36.000 30.000 vs. 6.000 6.000 vs. 36.000 Comparisons for fa Comparison 6.000 vs. 36.000	Diff of Means 0.345 0.101 0.244 actor: AGE with Diff of Means 0.201	p 3 2 2 nin H 3	q 1.946 0.569 1.377 q 1.137	0.366 0.690 I 0.338 I P 0.703	No Do Not Test Do Not Test P<0.05 No
Comparison 30.000 vs. 36.000 30.000 vs. 6.000 6.000 vs. 36.000 Comparisons for fa Comparison	Diff of Means 0.345 0.101 0.244 actor: AGE with Diff of Means 0.201	p 3 2 2 nin H 3	q 1.946 0.569 1.377	0.366 0.690 I 0.338 I P 0.703 0.736 I	No Do Not Test Do Not Test P<0.05

Experimente	≘r ⊃a	tyanarayana	I In ALCONDENSE								
Date	20	08/04/24		Projec	t	Aging an	d Aortic Stiffi	ness			
Report Num	iber A	SMEDL-01		Tissue	/ cell line/ et	c. F1 DIAPH	RAGM - Cyto	solic Fracti	on		
Gel type		10%		Electro	Electrophoresis Voltage 124				Transfer Voltage 25		
^o rotien Loac	d per Well	50 ug		 Durati	Duration 01:30 hrs			Duration 45minutes			5
Primary Antibody						Seco	ndary A	ntibody			
Name (Do Not Abbreviate) Mammalian Target of			of rapamyci	n (m-TOR)		Name	Anti Ral	obit			
Dilution 1:1000 Medium			ım 5% BSA	A in TBST		Dilution	n 1:1000	M	edium 5% N	Ailk in TBS	
Incubation time Overnight				47			Incubat	ion time	1:00hr	6	
Lane #1	Lane # 2	Lane # 3	Lane # 4	Lane # 5	Lane # 6	Lane # 7	Lane # 8	Lane # 9	Lane # 10	Lane # 11	Lane # 12
BL	MW	6m Male	30m Male	36m Male	Sample Buffer	6m	26m	30m	Sample	Positive	Sample
				6 .30 3 Malis	× 12,	Female	Female	Female	Buffer	Control Exposure t 5 minute Molecular V 289	Buffer
		Plac	The Scan of F		2 16 1 - DIAF 000) m 000) An 24/2008	26 30 Cemal	1921 +	Female	Buffer	Exposure t 5 minute Molecular V 289	Buffer
.ocation of S	Scan		ce Scan of F	-ilm Here	× 12,	26 30 Cernal PHRAGI 5-JOR It: Ra Raf	n-Q Auct			Exposure t 5 minute Molecular V 289	Buffer ime Vieght
		\\Blough	ce Scan of F n-raid\exp-da	Film Here ata\Project fi	× 16 - DIAF 000) m 24/2008	28 30 Canal HRAG HRAG Li Rag Rag	ness\FILMS\I	DIAPHRAGI	J V\mTOR	Exposure t 5 minute Molecular V 289	Buffer
		\\Blough	ce Scan of F n-raid\exp-da	Film Here ata\Project fi	- DiAf 000) m 000) An 24 2008	28 30 Canal HRAG HRAG Li Rag Rag	ness\FILMS\I	DIAPHRAGI	J V\mTOR	Exposure t 5 minute Molecular V 289	Buffer
ocation of E		\\Blough	ce Scan of F n-raid\exp-da	Film Here ata\Project fi	- DiAf 000) m 000) An 24 2008	28 30 Canal HRAG HRAG Li Rag Rag	ness\FILMS\I	DIAPHRAGI	J V\mTOR	Exposure t 5 minute Molecular V 289	Buffer
Location of S Location of E Notes		\\Blough	ce Scan of F n-raid\exp-da	Film Here ata\Project fi	- DiAf 000) m 000) An 24 2008	28 30 Canal HRAG HRAG Li Rag Rag	ness\FILMS\I	DIAPHRAGI	V\mTOR 1	Exposure t 5 minute Molecular V 289	Buffer ime Vieght r Analysis

	6m male	30m male	36m male	6m female	26m female	30m female
	10.6	10.1	13	12.1	24.2	30
	10.8	9.7	13.3	11.8	24.6	29.7
	11.8	15.8	13.2	14.5	21.1	23.7
	10.7	17.3	13.3	16	20	22.7
	3.8	20	23.8	14.1	19.5	18.9
	3.6	20	23.6	15.2	19.4	18.2
Ν	6	6	6	6	6	6
Mean	8.55	15.48	16.70	13.95	21.47	23.87
SD	3.78	4.62	5.42	1.68	2.35	5.10
SEM	1.69	2.07	2.43	0.75	1.05	2.28

Two Way Analysis of Variance

Comparisons for f	actor: Age within	n M			
Comparison	Diff of Means	t	Unadjusted P	Critical Level	Significant?
36.000 vs. 6.000	8.150	3.469	0.002	0.017	Yes
30.000 vs. 6.000	6.933	2.951	0.006	0.025	Yes
36.000 vs. 30.000	1.217	0.518	0.608	0.050	No
Comparisons for f	actor: A go with i	n F			
Comparison	Diff of Means	t	Unadjusted P	Critical Level	Significant?
36.000 vs. 6.000	9.917	4.220	0.000	0.017	Yes
30.000 vs. 6.000	7.517	3.199	0.003	0.025	Yes
36.000 vs. 30.000	2.400	1.021	0.315	0.050	No
Comparisons for f	actor: Sex withir Diff of Means	n 6 t	Unadjusted P	Critical Level	Significant?
F vs. M	5.400	ι 2.298	0.029	0.050	Yes
1 V.S. 1VI	5.400	2.270	0.027	0.050	105

Comparisons for factor: Sex within 30									
Comparison	Diff of Means	t	Unadjusted P	Critical Level	Significant?				
F vs. M	5.983	2.546	0.016	0.050	Yes				

Comparisons for factor: Sex within 36									
Comparison	Diff of Means	t	Unadjusted P	Critical Level	Significant?				
F vs. M	7.167	3.050	0.005	0.050	Yes				

10000 12	er S	atyanarayana	Paturi							Prin	it i offici	
Date	2	008/04/24		Projec	t	Aging an	d Aortic Stiffr	ness				
Report Num	nber A	SMEDL-01		Tissue	/ cell line/ et	tc. F1 DIAPH	IRAGM - Cyto	solic Fraction	on			
Gel type		10%		Electro	Electrophoresis Voltage 124			Tran	Transfer Voltage 25			
Protien Load per Well 50 ug			Durati	Duration 01:30 hrs				Duration	45minute	5		
Primary Antibody						Secor	ndary Ai	ntibody				
Name (Do Not Abbreviate) phospho-mammalian				an Target of	rapamycin ((p-m-TOR)	Name	Anti Rał				
Dilution 1:1000 Medium			m 5% BSA	in TBST		Dilution	1:1000	Me	edium 5% N	/lilk in TBST		
Incubation time Overnight				21			Incubat	ion time	1 : 00hr	<u>.</u>		
Lane #1	Lane # 2	Lane # 3	Lane # 4	Lane # 5	Lane # 6	Lane # 7	Lane # 8	Lane # 9	Lane # 10	Lane # 11	Lane # 12	
BL	MW	6m Male	30m Male	36m Male	Sample Buffer	6m Female	26m Female	30m Female	Sample Buffer	Positive Control	Sample Buffer	
			-				ř 📄			5.07 		
			1.00	30 3 1.600 (1.50) p-n p-n 0) An 07/23/	25 20, emale DJOR ti Rak 2008	sit aturi			Molecular V 289	Vieght	
		Plac	re Scan of F) p-n p-n o) An 07/23/	25 20, male TOR ti Rak 2008	i) soit atui		Ī			
Location of	Scan		e Scan of F	ilm Here			iness/FILMS/I	DIAPHRAGN		289		
Location of		\\Blough	ce Scan of F n-raid\exp-da	Film Here	older\Aging	& aortic stiff			ı, ∕l\p-mTOR	289		
		\\Blough	ce Scan of F n-raid\exp-da	Film Here	older\Aging	& aortic stiff	ness\FILMS\I		ı, ∕l\p-mTOR	289		
Location of		\\Blough	ce Scan of F n-raid\exp-da	Film Here	older\Aging	& aortic stiff	ness\FILMS\I		/\p-mTOR	289	r Analysis	

	6m male	30m male	36m male	6m female	26m female	30m female
	1.09	1.92	1.68	1.49	0.67	0.43
	1.12	2.00	1.62	1.53	0.62	0.45
	1.01	1.00	1.39	0.96	0.95	0.84
	1.08	0.97	1.33	0.86	1.02	0.88
	2.16	0.94	0.87	1.26	0.76	1.05
	2.22	0.91	0.89	1.19	0.77	1.09
Ν	6	6	6	6	6	6
Mean	1.45	1.29	1.30	1.21	0.80	0.79
SD	0.58	0.52	0.35	0.27	0.16	0.29
SEM	0.26	0.23	0.16	0.12	0.07	0.13

Two Way Analysis of Variance

Comparisons for fac	ctor: SEX with	in 6			
Comparison D		р	q	Р	P<0.05
M vs. F	0.233	2	1.466	0.308	No
Comparisons for fac	ctor: SEX with	in 3	0		
Comparison D	Diff of Means	р	q	Р	P<0.05
M vs. F	0.491	2	3.089	0.037	Yes
Comparisons for fac	ctor: SEX with	in 3	6		
Comparison D	Diff of Means	р	q	Р	P<0.05
M vs. F	0.505	2	3.176	0.032	Yes
Comparisons for fac Comparison D	Diff of Means	р	q	Р	P<0.05
6.000 vs. 30.000	0.159	3	1.002		No
6.000 vs. 36.000	0.152		0.955		Do Not Test
36.000 vs. 30.000	0.00750	2	0.0472	0.974 I	Do Not Test
Comparisons for fac				-	-
Comparison D		p	q	P	P<0.05
6.000 vs. 36.000	0.423	3	2.664	0.161	No
6.000 vs. 30.000	0.417	2	2.625	0.073 I	Do Not Test

30.000 vs. 36.000 0.00628 2 0.0395 0.978 Do Not Test

	er Sa	atyanarayana	Paturi							Prir	t Form
Date	20	008/04/24		Projec	t	Aging and	d Aortic Stiffi	ness			
Report Num	nber A	SMEDL-01		Tissue	/ cell line/ et	tc. F1 DIAPH	RAGM - Cyto	solic Fracti	on		
Gel type		10%		Electro	ophoresis Vo	ltage 124		Tran	sfer Voltage	25	
Protien Load	d per Well	50 ug		 Durati	on	01:3	0 hrs	<u></u>	Duration	45minute	5
Primary	Antiboo	dy					Secor	ndary Aı	ntibody		
Name (Do N			mal protein	S6 kinase (P	70S6K)		Name	- Anti Ral			
Dilution 1:	:1000	14	Mediu	ım 5% BSA	A in TBST		Dilution	1:1000	Me	edium 5% N	Ailk in TBST
Incubation 1	time Ove	ernight		~			Incubation time 1:00hr				
Lane #1	Lane # 2	Lane # 3	Lane # 4	Lane # 5	Lane # 6	Lane # 7	Lane # 8	Lane # 9	Lane # 10	Lane # 11	Lane # 12
BL	MW	6m Male	30m Male	36m Male	Sample Buffer	6m Female	26m Female	30m Female	Sample Buffer	Positive Control	Sample Buffer
				1°(1:1 2°(1:1	=	A-C Fema 6 26 HOSEL Mt: Rab	- 			Molecular V 70	/ieght
l ocation of	Scan		ce Scan of F	ilm Here		Patu & actic stiff				Z Used Fo	r Analysis
		\\Blough	ce Scan of F n-raid\exp-da	Film Here	older\Aging	& aortic stiff	ness\FILMS\[/∿P70S6k	▼ Used Fo	r Analysis
		\\Blough	ce Scan of F n-raid\exp-da	Film Here	older\Aging	& aortic stiff			/∿P70S6k	▼ Used Fo	r Analysis
		\\Blough	ce Scan of F n-raid\exp-da	Film Here	older\Aging	& aortic stiff	ness\FILMS\[/∿P70S6k	Z Used Fo	r Analysis
Location of Location of Notes		\\Blough	ce Scan of F n-raid\exp-da	Film Here	older\Aging	& aortic stiff	ness\FILMS\[/\P7056k	Used Fo	

	6m male	30m male	36m male	6m female	26m female	30m female
	13.6	18.4	14	19.1	18.6	16.2
	13.6	18.3	13.9	19.4	18.6	16.2
	8.5	22.1	17.4	16.7	17.8	17.4
	8.1	22.7	17.7	16.5	18	17.1
	11.9	18.9	17	17.7	16.8	17.7
	11.8	19	16.9	17.7	16.9	17.7
Ν	6	6	6	6	6	6
Mean	11.25	19.90	16.15	17.85	17.78	17.05
SD	2.42	1.96	1.73	1.20	0.79	0.69
SEM	1.08	0.88	0.77	0.53	0.35	0.31

Two Way Analysis of Variance

Comparisons for fa	actor: Age withi	in M			
Comparison	Diff of Means	р	q	Р	P<0.05
30.000 vs. 6.000	8.650	3	13.296	< 0.001	Yes
30.000 vs. 36.000	3.750	2	5.764	< 0.001	Yes
36.000 vs. 6.000	4.900	2	7.532	<0.001	Yes
Comparisons for fa	actor: Age with i	in F			
Comparison	Diff of Means	р	q	Р	P<0.05
6.000 vs. 36.000	0.800	3	1.230	0.663	No
6.000 vs. 30.000	0.0667	2	0.102	0.943 I	Do Not Test
30.000 vs. 36.000	0.733	2	1.127	0.432 I	Do Not Test
Comparisons for fa Comparison F vs. M	actor: Sex withi Diff of Means 6.600	n 6 p 2	q 10.145	P <0.001	P<0.05 Yes
	~	•			
A	Diff of Means	р	q	Р	P<0.05
Comparison M vs. F Comparisons for fa	Diff of Means 2.117	p 2	q 3.253 q	Р 0.029 Р	P<0.05 Yes P<0.05

RI MW 6m Male 30m Male 36m Male Sample 6m 26m 30m Sample Positive Samp	Experiment	er S	atyanarayana	Paturi							Prir	nt Form
Gel type 10% Electrophoresis Voltage 124 Transfer Voltage 25 Proten Load per Well 50 ug Duration 01:30 hrs Duration 45minutes Primary Antibody Secondary Antibody Secondary Antibody Name (Do Not Abbreviate) phospho-fillosomal protein56 kinase(p-p7056K-389) Name Anti-Rabbit Dilution 1:1000 Medium 5% BSA in TBST Dilution 1:500 Medium 5% Milk in Tilloody Incubation time Overnight Incubation time 1:00hr Medium 5% Milk in Tilloody Lane #1 Lane #2 Lane #3 Lane #4 Lane #5 Lane #6 Lane #7 Lane #8 Lane #9 Lane #1 Lane #3 BL MW 6m Male 30m Male Sample 6m 25m 30m Sample Positive Sample Sample Control Buffer Gel XW 6m Male 30m Male 36m Male Sample 6m 25m 30m Sample 70.85 200 200 200 200 200 200 200 200 200 200 </td <td>Date</td> <td>2</td> <td>008/11/13</td> <td></td> <td>– Projec</td> <td>t</td> <td>Aging an</td> <td>d Aortic Stiffi</td> <td>ness</td> <td></td> <td></td> <td></td>	Date	2	008/11/13		– Projec	t	Aging an	d Aortic Stiffi	ness			
Protein Load per Well 50 ug Duration 01:30 hrs Duration 45minutes Primary Antibody Name (Do Not Abbreviate) phospho-Ribosomal protein56 kinase(p-p7056K-389) Lacation of Scan NBlowgh-raid/exp-data/Project folder/Aging & aortic stiffness/ELMS/DIAPHRAGM/p-p7056K-389 Notes	Report Num	nber A	SMEDL-01		Tissue	/ cell line/ et	tc. F1 DIAPH	IRAGM - Cytc	solic Fracti	on		
Primary Antibody Secondary Antibody Name (Do Not Abbreviate) phospho-Ribosomal protein56 kinase(p-p7056K-389) Name Anti-Rabbit Dilution 11000 Medium 5% BSA in TBST Dilution 1:500 Medium 5% Milk in TI Incubation time Overnight Incubation time Overnight Incubation time 1:00hr Lane #1 Lane #2 Lane #3 Lane #4 Lane #5 Lane #6 Lane #7 Lane #8 Lane #9 Lane #10 Lane #11 Lane #13 BL MW Gm Male 30m Male 36m Male Sample 6m 26m 30m Sample Positive Sample G 30m Male 36m Male Sample 6m 26m 30m Sample Positive Sample AGLING - DIA - 8 0 6 30.035 6 30.056 Sample Positive Sample AGLING - DIA - 8 0 Female 26m 30m Sample Positive Sample Jo 200 385 6 30.056 Sample Positive Sample Positive Sample	Gel type		10%		Electro	ophoresis Vo	ltage 124		Tran	sfer Voltage	25	
Name (Do Not Abbreviate) phospho-Ribosomal protein56 kinase(p-p7056K-389) Name Arti-Rabbit Dilution 1:000 Medium 5% BSA in TBST Dilution 1:500 Medium 5% Milkin T Incubation time Overnight Incubation time 1:00hr 1:00hr Medium 5% Milkin T Incubation time Overnight Incubation time 1:00hr Incubation time 1:00hr Incubation time Overnight Incubation time 1:00hr Incubation time 1:00hr Incubation time Overnight Incubation time 1:00hr Incubation time 1:00hr Incubation time Overnight Incubation time 1:00hr Incubation time 1:00hr Incubation time Overnight Incubation time 1:00hr Incubation time 1:00hr Incubation time Overnight Incubation time 1:00hr Incubation time 1:00hr Incubation time Overnight Incubation time Incubation time 1:00hr Incubation time Overnight Incubation time Incubation time Incubation time Incubation <	Protien Loa	d per Well	50 ug		 Durati					Duration	45minute	s
Name (O Not Abbreviate) phospho-Ribosomal protein56 kinse(p-p7056K-389) Name Arti-Rabbit Dilution 1:000 Medium 5% BSA in TBST Dilution 1:500 Medium 5% Milk in T Incubation time Overnight Incubation time 1:00hr 1:00hr Incubation time 1:00hr Incubation time Overnight Incubation time 1:00hr Incubation time 1:00hr Incubation time Overnight Incubation time 1:00hr Incubation time 1:00hr Incubation time Overnight Incubation time 1:00hr Incubation time 1:00hr Incubation time Overnight Incubation time 1:00hr Incubation time 1:00hr BL MW 6m Male 30m Male 36m Male Sample 6m Sample Control Buffer Incubation time 01Ar 8 Infer Infer Infer Control Buffer Control Buffer Control Buffer Infer	Primary	Antiboo	dy					Seco	ndary A	ntibody		
Incubation time Overnight Incubation time 1:00rr Lane #1 Lane #2 Lane #3 Lane #4 Lane #5 Lane #6 Lane #7 Lane #8 Lane #10 Lane #11 Lane #11 Lane #11 BL MW 6m Male 30m Male 36m Male Sample Buffer 6m 26m 30m Sample Buffer Female Buffer Control Buffer AGING - 01A - 8 0 0 AGING - 01A - 8 0 0 Molecular Wieght 10' 6 30 33 6 31 30' Molecular Wieght 70, 85 Place Scan of Film Here Place Scan of Film Here Vised For Analy Incubation of Scan Vised For Analy Location of Scan Viseouph-raid/exp-data/Project folder/Aging & aortic stiffness/ELMS/DIAPHRAGM/p-p7056k-389 Viseouph-raid/exp-data/Project folder/Aging & aortic stiffness/ExcehDIAPHRAGM Notes	510			o-Ribosomal	proteinS6	kinase(p-p7(DS6K-389)		1570			
Lane #1 Lane #2 Lane #3 Lane #4 Lane #5 Lane #6 Lane #7 Lane #8 Lane #9 Lane #10 Lane #11	Dilution 1	:1000		Mediun	n 5% BS#	A in TBST		Dilution	n 1:500	Me	edium 5% l	Ailk in TBST
BL MW 6m Male 30m Male 36m Male Sample Buffer 6m Female 26m Female 30m Female Sample Buffer Positive Control Sample Buffer AGING - DIA - 8 0 Image: Sample	Incubation	time Ove	ernight		~			Incubat	ion time	1 : 00hr	ξα.	
BL MW om Male SUM Male SUM Male Sum Male Buffer Female Female Female Buffer Control Buffer AGING - DIA - 8 0 Image: Sum Male AGING - DIA - 8 0 Image: Sum Male Image: Sum Male Exposure time 10 ⁻¹ AGING - DIA - 8 0 Image: Sum Male Sum Male Sum Male Sum Male Sum Male Image: Sum Male Image	Lane #1	Lane # 2	Lane # 3	Lane # 4	Lane # 5	Lane # 6	Lane # 7	Lane # 8	Lane # 9	Lane # 10	Lane # 11	Lane # 12
Location of Scan \\Blough-raid\exp-data\Project folder\Aging & aortic stiffness\FILMS\DIAPHRAGM\ Notes	BL	MW	6m Male	30m Male	36m Male					2006		Sample Buffer
Location of Excel Data \\Blough-raid\exp-data\Project folder\Aging & aortic stiffness\Excel\DIAPHRAGM Notes				6 m 1°C "2°C "10"	30 36, alus 1:500 1-500 5 [200]					ŀ	Molecular V 70, 85	
Notes	Location of	Scan	\\Blough	ı-raid∖exp-dat	a\Project f	older\Aging	& aortic stiff	ness\FILMS\I	DIAPHRAGI	N\p-p70S6k-	389	
	Location of	Excel Data	\\Blough	ı-raid∖exp-dat	a\Project f	older\Aging	& aortic stiff	ness\Excel\D	NAPHRAGN	1		
email Report	Notes											
										e	mail Report	
Signature	Signati	ure										

Laboratory of Molecular Physiology, Marshall University, Science Bldg. Suite 311, 1 John Marshall Drive, Huntington, WV, 25755 * Phone: 304-696-3267 Fax: 304-696-7136 http://www.science.marshall.edu/blough

	6m male	30m male	36m male	6m female	26m female	30m female
	0.60	0.78	1.30	1.02	1.17	1.11
	0.57	0.80	1.33	1.00	1.18	1.09
	1.18	0.73	1.11	1.22	1.24	0.99
	1.21	0.73	1.07	1.24	1.23	1.02
	0.66	0.75	1.08	1.11	1.32	1.01
	0.68	0.75	1.09	1.10	1.30	1.01
Ν	6	6	6	6	6	6
Mean	0.82	0.76	1.16	1.12	1.24	1.04
SD	0.29	0.03	0.12	0.10	0.06	0.05
SEM	0.13	0.01	0.05	0.04	0.03	0.02

Two Way Analysis of Variance

Comparisons for fac		in 6			
Comparison I	Diff of Means	р	q	Р	P<0.05
F vs. M	0.301	2	5.251	< 0.001	Yes
Comparisons for fac Comparison I F vs. M		in 3 p 2	q	P <0.001	P<0.05 Yes
Comparisons for fa	ctor: SEX with	in 3	6		
Comparison I	Diff of Means	р	q	Р	P<0.05
M vs. F	0.125	2	$2.\bar{1}91$	0.132	No
Comparisons for factor for factor factor for factor for the second secon	ctor: AGE witl Diff of Means	hin N p	VI q	Р	P<0.05
36.000 vs. 30.000					Yes
36.000 vs. 6.000					
6.000 vs. 30.000				0.475	No
Comparisons for fa				Ð	D 0 05
Comparison I		р	q		P<0.05
	0 000	2			
30.000 vs. 36.000 30.000 vs. 6.000			3.489 2.129	0.050 0.143	Yes No

0.0779

2 1.361

0.344

No

6.000 vs. 36.000

Experimente										Prir	nt Form
Date	-	Satyanarayana 2008/04/24	ar dean	 Projec	-+	Aging an	d Aortic Stiffr	1655		and the second s	
Report Num	<u>12</u>	ASMEDL-01					IRAGM - Cyto		00		
Report Num	=				e/ cell line/ etc			Solic Hacti	011		
Gel type		10%		Electro	ophoresis Vol	tage 124		Tran	sfer Voltage	25	
Protien Load	d per Wel	50 ug		Durati	on	01:3	30 hrs		Duration	45minute	5
Primary	Antibo	dy					Secor	ndary A	ntibody		
Name (Do N	ot Abbre	viate) Calcine	eurin A (CnA)				Name	Anti Ral	obit		
Dilution 1:	1000		Mediu	m 5% BS/	A in TBST		Dilution	1:1000	M	edium 5% N	Ailk in TBST
Incubation t	ime O\	vernight		2			Incubat	ion time	1:00hr	6	
Lane #1	Lane # 2	2 Lane # 3	Lane # 4	Lane # 5	Lane # 6	Lane # 7	Lane # 8	Lane # 9	Lane # 10	Lane # 11	Lane # 12
BL	MW	6m Male	30m Male	36m Male	Sample Buffer	6m Female	26m Female	30m Female	Sample Buffer	Positive Control	Sample Buffer
		2		AGIN Ma	00.00	6	9/ 25)				
				2°(1: 1°(1:1 09	- -	anti M	-	4		Molecular V 61 Kda	
			ce Scan of F	2(1: 1°(1:1 09]	1000) A 000) C 103/2008	enti M	laute haute			61 Kda ✓ Used Fo	
Location of 2	Scan		ce Scan of F	2(1: 1°(1:1 09]	1000) A 000) C 103/2008	enti M	n ause			61 Kda ✓ Used Fo	_
		\\Blougl	ce Scan of F h-raid\exp-da	2(1: 1°(1:1 09 film Here	1000) A	enti h alcir galcir gaortic stiff	laute haute	DIAPHRAGI	M\Calcineuri	61 Kda ✓ Used Fo	
Location of 1 Location of 1 Notes		\\Blougl	ce Scan of F h-raid\exp-da	2(1: 1°(1:1 09 film Here	1000) A	enti h alcir galcir gaortic stiff	heress FILMS	DIAPHRAGI	M\Calcineuri	61 Kda ✓ Used Fo	
Location of I		\\Blougl	ce Scan of F h-raid\exp-da	2(1: 1°(1:1 09 film Here	1000) A	enti h alcir galcir gaortic stiff	heress FILMS	DIAPHRAGI	M\Calcineuri	61 Kda ✓ Used Fo	_

	6m male	30m male	36m male	6m female	26m female	30m female
	5.70	12.30	21.30	13.20	21.30	26.10
	5.50	12.20	21.40	13.20	21.60	26.10
	3.80	4.70	17.90	19.20	27.60	26.80
	4.40	5.10	17.60	18.60	27.80	26.50
	4.50	7.50	21.00	20.10	24.20	22.60
_	4.30	7.40	22.60	19.10	24.00	22.60
Ν	6	6	6	6	6	6
Mean	4.70	8.20	20.30	17.23	24.42	25.12
SD	0.74	3.34	2.05	3.16	2.81	1.97
SEM	0.33	1.49	0.92	1.41	1.26	0.88

Two Way Analysis of Variance

Comparisons for f	actor: Age withi	n M			
Comparison	Diff of Means	р	q	Р	P<0.05
36.000 vs. 6.000	0.961	3	10.690	< 0.001	Yes
36.000 vs. 30.000	0.732	2	8.138	< 0.001	Yes
30.000 vs. 6.000	0.229	2	2.552	0.081	No
Comparisons for f	actor: A go with i	n F			
Comparisons for f	Diff of Means		a	Р	P<0.05
30.000 vs. 6.000	0.347	р 3	q 3.864	—	Yes
30.000 vs. 36.000	0.106	2	1.184	0.028	No
36.000 vs. 6.000	0.241	$\frac{2}{2}$	2.680	0.409	No
50.000 vs. 0.000	0.271	2	2.000	0.000	110
Comparisons for f	actor: Sex within	n 6			
1					
Comparison			q	Р	P<0.05
Comparison F vs. M	Diff of Means 0.906	р 2	q 10.074	P <0.001	P<0.05 Yes
-	Diff of Means	р	-		
F vs. M Comparisons for f	Diff of Means 0.906 actor: Sex withi	p 2	-		Yes
F vs. M Comparisons for f Comparison	Diff of Means 0.906 actor: Sex within Diff of Means	р 2 n 30 р	10.074 q	<0.001 P	
F vs. M Comparisons for f	Diff of Means 0.906 actor: Sex withi	р 2 n 30	10.074	<0.001 P	Yes
F vs. M Comparisons for f Comparison	Diff of Means 0.906 actor: Sex within Diff of Means	р 2 n 30 р	10.074 q	<0.001 P	Yes P<0.05
F vs. M Comparisons for f Comparison	Diff of Means 0.906 actor: Sex within Diff of Means 1.024	p 2 n 30 p 2	10.074 q	<0.001 P	Yes P<0.05
F vs. M Comparisons for f Comparison F vs. M	Diff of Means 0.906 actor: Sex within Diff of Means 1.024	p 2 n 30 p 2	10.074 q	<0.001 P	Yes P<0.05

REFERENCES

- Janssen, I., et al., *The healthcare costs of sarcopenia in the United States*. J Am Geriatr Soc, 2004.
 52(1): p. 80-5.
- Rantanen, T., *Muscle strength, disability and mortality.* Scand J Med Sci Sports, 2003. 13(1): p. 3-8.
- 3. Lauretani, F., et al., *Age-associated changes in skeletal muscles and their effect on mobility: an operational diagnosis of sarcopenia.* J Appl Physiol, 2003. **95**(5): p. 1851-60.
- 4. Rolland, Y., et al., *Sarcopenia: its assessment, etiology, pathogenesis, consequences and future perspectives.* J Nutr Health Aging, 2008. **12**(7): p. 433-50.
- 5. Fulle, S., S. Belia, and G. Di Tano, *Sarcopenia is more than a muscular deficit*. Arch Ital Biol, 2005. **143**(3-4): p. 229-34.
- Lipman, R.D., et al., Pathologic characterization of brown Norway, brown Norway x Fischer 344, and Fischer 344 x brown Norway rats with relation to age. J Gerontol A Biol Sci Med Sci, 1996.
 51(1): p. B54-9.
- 7. Tanaka, S., et al., *Establishment of an Aging Farm of F344/N Rats and C57BL/6 Mice at the National Institute for Longevity Sciences (NILS).* Arch Gerontol Geriatr, 2000. **30**(3): p. 215-223.
- 8. Kinnard, R.S., et al., *Regulation of p70S6k, GSK-3beta, and calcineurin in rat striated muscle during aging.* Biogerontology, 2005. **6**(3): p. 173-84.
- 9. Fried, L.P., *Epidemiology of aging*. Epidemiol Rev, 2000. **22**(1): p. 95-106.
- 10. Rice, K.M., et al., *The Fischer 344/NNiaHSd X Brown Norway/BiNia is a better model of sarcopenia than the Fischer 344/NNiaHSd: a comparative analysis of muscle mass and contractile properties in aging male rat models.* Biogerontology, 2005. **6**(5): p. 335-43.
- 11. Caccia, M.R., J.B. Harris, and M.A. Johnson, *Morphology and physiology of skeletal muscle in aging rodents*. Muscle Nerve, 1979. **2**(3): p. 202-12.
- 12. Sato, T., et al., *Age changes in size and number of muscle fibers in human minor pectoral muscle.* Mech Ageing Dev, 1984. **28**(1): p. 99-109.
- 13. Doherty, T.J., *Invited review: Aging and sarcopenia*. J Appl Physiol, 2003. **95**(4): p. 1717-27.
- 14. Blough, E.R. and J.K. Linderman, *Lack of skeletal muscle hypertrophy in very aged male Fischer* 344 x Brown Norway rats. J Appl Physiol, 2000. **88**(4): p. 1265-70.
- 15. Baar, K. and K. Esser, *Phosphorylation of p70(S6k) correlates with increased skeletal muscle mass following resistance exercise.* Am J Physiol, 1999. **276**(1 Pt 1): p. C120-7.
- 16. Bodine, S.C., et al., *Identification of ubiquitin ligases required for skeletal muscle atrophy.* Science, 2001. **294**(5547): p. 1704-8.
- 17. Dorn, G.W., 2nd and T. Force, *Protein kinase cascades in the regulation of cardiac hypertrophy*. J Clin Invest, 2005. **115**(3): p. 527-37.
- 18. Gingras, A.C., B. Raught, and N. Sonenberg, *Control of translation by the target of rapamycin proteins*. Prog Mol Subcell Biol, 2001. **27**: p. 143-74.
- 19. Czarkowska-Paczek, B. and S. Milczarczyk, *[Age-related muscle mass loss]*. Przegl Lek, 2006. **63**(8): p. 658-61.
- 20. Larsson, L., G. Grimby, and J. Karlsson, *Muscle strength and speed of movement in relation to age and muscle morphology.* J Appl Physiol, 1979. **46**(3): p. 451-6.
- 21. Marzetti, E. and C. Leeuwenburgh, *Skeletal muscle apoptosis, sarcopenia and frailty at old age.* Exp Gerontol, 2006. **41**(12): p. 1234-8.
- 22. Kelijman, M., *Age-related alterations of the growth hormone/insulin-like-growth-factor I axis.* J Am Geriatr Soc, 1991. **39**(3): p. 295-307.
- 23. Pekary, A.E., et al., *Preferential release of triiodothyronine: an intrathyroidal adaptation to reduced serum thyroxine in aging rats.* J Gerontol, 1983. **38**(6): p. 653-9.

- 24. Nankin, H.R. and J.H. Calkins, *Decreased bioavailable testosterone in aging normal and impotent men.* J Clin Endocrinol Metab, 1986. **63**(6): p. 1418-20.
- 25. Gutmann, E. and V. Hanzlikova, *Motor unit in old age.* Nature, 1966. **209**(5026): p. 921-2.
- 26. Gutmann, E. and V. Hanzlikova, *Fast and slow motor units in ageing.* Gerontology, 1976. **22**(4): p. 280-300.
- 27. Larsson, L., *Motor units: remodeling in aged animals.* J Gerontol A Biol Sci Med Sci, 1995. **50 Spec No**: p. 91-5.
- 28. Larsson, L. and T. Ansved, *Effects of ageing on the motor unit.* Prog Neurobiol, 1995. **45**(5): p. 397-458.
- 29. Brooks, S.V. and J.A. Faulkner, *Contraction-induced injury: recovery of skeletal muscles in young and old mice*. Am J Physiol, 1990. **258**(3 Pt 1): p. C436-42.
- 30. Faulkner, J.A., S.V. Brooks, and E. Zerba, *Muscle atrophy and weakness with aging: contractioninduced injury as an underlying mechanism.* J Gerontol A Biol Sci Med Sci, 1995. **50 Spec No**: p. 124-9.
- 31. Carlson, B.M., *Factors influencing the repair and adaptation of muscles in aged individuals: satellite cells and innervation.* J Gerontol A Biol Sci Med Sci, 1995. **50 Spec No**: p. 96-100.
- 32. Wanagat, J., et al., *Mitochondrial DNA deletion mutations colocalize with segmental electron transport system abnormalities, muscle fiber atrophy, fiber splitting, and oxidative damage in sarcopenia.* Faseb J, 2001. **15**(2): p. 322-32.
- 33. Weindruch, R., *Interventions based on the possibility that oxidative stress contributes to sarcopenia.* J Gerontol A Biol Sci Med Sci, 1995. **50 Spec No**: p. 157-61.
- 34. Young, A., M. Stokes, and M. Crowe, *Size and strength of the quadriceps muscles of old and young women*. Eur J Clin Invest, 1984. **14**(4): p. 282-7.
- 35. Young, A., M. Stokes, and M. Crowe, *The size and strength of the quadriceps muscles of old and young men.* Clin Physiol, 1985. **5**(2): p. 145-54.
- 36. Imamura, K., et al., *Human major psoas muscle and sacrospinalis muscle in relation to age: a study by computed tomography.* J Gerontol, 1983. **38**(6): p. 678-81.
- 37. Klitgaard, H., et al., *Ageing alters the myosin heavy chain composition of single fibres from human skeletal muscle*. Acta Physiol Scand, 1990. **140**(1): p. 55-62.
- 38. Rice, C.L., et al., *Arm and leg composition determined by computed tomography in young and elderly men.* Clin Physiol, 1989. **9**(3): p. 207-20.
- 39. Rice, C.L., et al., *A comparison of anthropometry with computed tomography in limbs of young and aged men.* J Gerontol, 1990. **45**(5): p. M175-9.
- 40. Davies, C.T., M.J. White, and K. Young, *Muscle function in children*. Eur J Appl Physiol Occup Physiol, 1983. **52**(1): p. 111-4.
- 41. Alnaqeeb, M.A. and G. Goldspink, *Changes in fibre type, number and diameter in developing and ageing skeletal muscle.* J Anat, 1987. **153**: p. 31-45.
- 42. Holloszy, J.O., et al., *Skeletal muscle atrophy in old rats: differential changes in the three fiber types.* Mech Ageing Dev, 1991. **60**(2): p. 199-213.
- 43. Goldberg, A.L., et al., *Mechanism of work-induced hypertrophy of skeletal muscle*. Med Sci Sports, 1975. **7**(3): p. 185-98.
- 44. Pette, D. and G. Vrbova, *Neural control of phenotypic expression in mammalian muscle fibers.* Muscle Nerve, 1985. **8**(8): p. 676-89.
- 45. Welle, S., S. Totterman, and C. Thornton, *Effect of age on muscle hypertrophy induced by resistance training.* J Gerontol A Biol Sci Med Sci, 1996. **51**(6): p. M270-5.
- 46. Degens, H. and S.E. Alway, *Skeletal muscle function and hypertrophy are diminished in old age.* Muscle Nerve, 2003. **27**(3): p. 339-47.

- 47. Walters, T.J., H.L. Sweeney, and R.P. Farrar, *Influence of electrical stimulation on a fast-twitch muscle in aging rats.* J Appl Physiol, 1991. **71**(5): p. 1921-8.
- 48. Welle, S., *Cellular and molecular basis of age-related sarcopenia*. Can J Appl Physiol, 2002. **27**(1): p. 19-41.
- 49. Welle, S. and C.A. Thornton, *High-protein meals do not enhance myofibrillar synthesis after resistance exercise in 62- to 75-yr-old men and women.* Am J Physiol, 1998. **274**(4 Pt 1): p. E677-83.
- 50. Gollnick, P.D. and B. Saltin, *Significance of skeletal muscle oxidative enzyme enhancement with endurance training*. Clin Physiol, 1982. **2**(1): p. 1-12.
- 51. Gollnick, P.D., et al., *Muscular enlargement and number of fibers in skeletal muscles of rats.* J Appl Physiol, 1981. **50**(5): p. 936-43.
- 52. Timson, B.F. and G.A. Dudenhoeffer, *Skeletal muscle fibre number in the rat from youth to adulthood.* J Anat, 1990. **173**: p. 33-6.
- 53. Faulkner, J.A., et al., *Age-related changes in the structure and function of skeletal muscles.* Clin Exp Pharmacol Physiol, 2007. **34**(11): p. 1091-6.
- 54. Deschenes, M.R., *Effects of aging on muscle fibre type and size*. Sports Med, 2004. **34**(12): p. 809-24.
- 55. Musaro, A., et al., *Stem cell-mediated muscle regeneration is enhanced by local isoform of insulin-like growth factor 1.* Proc Natl Acad Sci U S A, 2004. **101**(5): p. 1206-10.
- 56. Musaro, A., et al., *Localized Igf-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle.* Nat Genet, 2001. **27**(2): p. 195-200.
- 57. Torella, D., et al., *Cardiac stem cell and myocyte aging, heart failure, and insulin-like growth factor-1 overexpression.* Circ Res, 2004. **94**(4): p. 514-24.
- 58. Bua, E.A., et al., *Mitochondrial abnormalities are more frequent in muscles undergoing sarcopenia*. J Appl Physiol, 2002. **92**(6): p. 2617-24.
- 59. Dirks, A.J. and C. Leeuwenburgh, *Tumor necrosis factor alpha signaling in skeletal muscle: effects of age and caloric restriction.* J Nutr Biochem, 2006. **17**(8): p. 501-8.
- 60. Pistilli, E.E., J.R. Jackson, and S.E. Alway, *Death receptor-associated pro-apoptotic signaling in aged skeletal muscle*. Apoptosis, 2006. **11**(12): p. 2115-26.
- 61. Dargelos, E., et al., *Involvement of the calcium-dependent proteolytic system in skeletal muscle aging*. Exp Gerontol, 2007. **42**(11): p. 1088-98.
- 62. Rao, A., C. Luo, and P.G. Hogan, *Transcription factors of the NFAT family: regulation and function*. Annu Rev Immunol, 1997. **15**: p. 707-47.
- 63. Dunn, S.E., E.R. Chin, and R.N. Michel, *Matching of calcineurin activity to upstream effectors is critical for skeletal muscle fiber growth*. J Cell Biol, 2000. **151**(3): p. 663-72.
- 64. McCullagh, K.J., et al., *NFAT is a nerve activity sensor in skeletal muscle and controls activitydependent myosin switching.* Proc Natl Acad Sci U S A, 2004. **101**(29): p. 10590-5.
- 65. Leger, B., et al., *Human sarcopenia reveals an increase in SOCS-3 and myostatin and a reduced efficiency of Akt phosphorylation.* Rejuvenation Res, 2008. **11**(1): p. 163-175B.
- 66. Siriett, V., et al., *Prolonged absence of myostatin reduces sarcopenia*. J Cell Physiol, 2006. **209**(3): p. 866-73.
- 67. Haddad, F. and G.R. Adams, *Aging-sensitive cellular and molecular mechanisms associated with skeletal muscle hypertrophy.* J Appl Physiol, 2006. **100**(4): p. 1188-203.
- 68. Bodine, S.C., et al., *Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo.* Nat Cell Biol, 2001. **3**(11): p. 1014-9.
- 69. Reynolds, T.H.t., S.C. Bodine, and J.C. Lawrence, Jr., *Control of Ser2448 phosphorylation in the mammalian target of rapamycin by insulin and skeletal muscle load*. J Biol Chem, 2002. **277**(20): p. 17657-62.

- 70. Parkington, J.D., et al., *Differential activation of mTOR signaling by contractile activity in skeletal muscle*. Am J Physiol Regul Integr Comp Physiol, 2003. **285**(5): p. R1086-90.
- 71. Bolster, D.R., et al., *Immediate response of mammalian target of rapamycin (mTOR)-mediated signalling following acute resistance exercise in rat skeletal muscle.* J Physiol, 2003. **553**(Pt 1): p. 213-20.
- 72. Sumino, Y., et al., *Growth mechanism of satellite cells in human urethral rhabdosphincter*. Neurourol Urodyn, 2007. **26**(4): p. 552-61.
- 73. Li, H., S. Malhotra, and A. Kumar, *Nuclear factor-kappa B signaling in skeletal muscle atrophy.* J Mol Med, 2008.
- 74. Barrett-Connor, E., *Estrogen and estrogen-progestogen replacement: therapy and cardiovascular diseases*. Am J Med, 1993. **95**(5A): p. 40S-43S.
- 75. Davison, S.L., et al., *Androgen levels in adult females: changes with age, menopause, and oophorectomy.* J Clin Endocrinol Metab, 2005. **90**(7): p. 3847-53.
- 76. Ashcroft, G.S. and J.J. Ashworth, *Potential role of estrogens in wound healing*. Am J Clin Dermatol, 2003. **4**(11): p. 737-43.
- 77. Doherty, T.J., *The influence of aging and sex on skeletal muscle mass and strength.* Curr Opin Clin Nutr Metab Care, 2001. **4**(6): p. 503-8.
- 78. Vandervoort, A.A. and A.J. McComas, *Contractile changes in opposing muscles of the human ankle joint with aging.* J Appl Physiol, 1986. **61**(1): p. 361-7.
- 79. Gallagher, D., et al., *Weight stability masks sarcopenia in elderly men and women*. Am J Physiol Endocrinol Metab, 2000. **279**(2): p. E366-75.
- 80. Baumgartner, R.N., et al., *Epidemiology of sarcopenia among the elderly in New Mexico*. Am J Epidemiol, 1998. **147**(8): p. 755-63.
- Iannuzzi-Sucich, M., K.M. Prestwood, and A.M. Kenny, *Prevalence of sarcopenia and predictors of skeletal muscle mass in healthy, older men and women*. J Gerontol A Biol Sci Med Sci, 2002.
 57(12): p. M772-7.
- 82. Melton, L.J., 3rd, S. Khosla, and B.L. Riggs, *Epidemiology of sarcopenia*. Mayo Clin Proc, 2000. **75 Suppl**: p. S10-2; discussion S12-3.
- 83. Frontera, W.R., et al., *Skeletal muscle fiber quality in older men and women*. Am J Physiol Cell Physiol, 2000. **279**(3): p. C611-8.
- 84. Baumgartner, R.N., et al., *Predictors of skeletal muscle mass in elderly men and women.* Mech Ageing Dev, 1999. **107**(2): p. 123-36.
- 85. Perry, H.M., 3rd, et al., *Testosterone and leptin in older African-American men: relationship to age, strength, function, and season.* Metabolism, 2000. **49**(8): p. 1085-91.
- 86. Szulc, P., et al., *Hormonal and lifestyle determinants of appendicular skeletal muscle mass in men: the MINOS study.* Am J Clin Nutr, 2004. **80**(2): p. 496-503.
- 87. Urban, R.J., et al., *Testosterone administration to elderly men increases skeletal muscle strength and protein synthesis.* Am J Physiol, 1995. **269**(5 Pt 1): p. E820-6.
- 88. Singh, M.A., et al., *Insulin-like growth factor I in skeletal muscle after weight-lifting exercise in frail elders.* Am J Physiol, 1999. **277**(1 Pt 1): p. E135-43.
- 89. Rice, K.M. and E.R. Blough, *Sarcopenia-related apoptosis is regulated differently in fast- and slow-twitch muscles of the aging F344/N x BN rat model.* Mech Ageing Dev, 2006. **127**(8): p. 670-9.
- 90. Gibson, M.C. and E. Schultz, *The distribution of satellite cells and their relationship to specific fiber types in soleus and extensor digitorum longus muscles.* Anat Rec, 1982. **202**(3): p. 329-37.
- 91. Franke, T.F., D.R. Kaplan, and L.C. Cantley, *PI3K: downstream AKTion blocks apoptosis*. Cell, 1997. **88**(4): p. 435-7.

- 92. Alessi, D.R., et al., *Mechanism of activation of protein kinase B by insulin and IGF-1.* Embo J, 1996. **15**(23): p. 6541-51.
- 93. Brown, E.J., et al., *A mammalian protein targeted by G1-arresting rapamycin-receptor complex.* Nature, 1994. **369**(6483): p. 756-8.
- 94. Sabatini, D.M., et al., *RAFT1: a mammalian protein that binds to FKBP12 in a rapamycindependent fashion and is homologous to yeast TORs.* Cell, 1994. **78**(1): p. 35-43.
- 95. Wiederrecht, G.J., et al., *Mechanism of action of rapamycin: new insights into the regulation of G1-phase progression in eukaryotic cells.* Prog Cell Cycle Res, 1995. **1**: p. 53-71.
- 96. Hornberger, T.A., et al., *mTOR is the rapamycin-sensitive kinase that confers mechanically-induced phosphorylation of the hydrophobic motif site Thr(389) in p70(S6k).* FEBS Lett, 2007. **581**(24): p. 4562-6.
- 97. Pansarasa, O., et al., *Oral amino acid supplementation counteracts age-induced sarcopenia in elderly rats.* Am J Cardiol, 2008. **101**(11A): p. 35E-41E.
- 98. Fang, Y., et al., *Phosphatidic acid-mediated mitogenic activation of mTOR signaling*. Science, 2001. **294**(5548): p. 1942-5.
- 99. Chou, M.M. and J. Blenis, *The 70 kDa S6 kinase: regulation of a kinase with multiple roles in mitogenic signalling.* Curr Opin Cell Biol, 1995. **7**(6): p. 806-14.
- 100. Klee, C.B., H. Ren, and X. Wang, *Regulation of the calmodulin-stimulated protein phosphatase, calcineurin.* J Biol Chem, 1998. **273**(22): p. 13367-70.
- 101. Horsley, V. and G.K. Pavlath, *NFAT: ubiquitous regulator of cell differentiation and adaptation.* J Cell Biol, 2002. **156**(5): p. 771-4.
- 102. Mitchell, P.O. and G.K. Pavlath, *Multiple roles of calcineurin in skeletal muscle growth.* Clin Orthop Relat Res, 2002(403 Suppl): p. S197-202.
- 103. Serrano, A.L., et al., *Calcineurin controls nerve activity-dependent specification of slow skeletal muscle fibers but not muscle growth*. Proc Natl Acad Sci U S A, 2001. **98**(23): p. 13108-13.
- 104. Kahl, C.R. and A.R. Means, *Regulation of cell cycle progression by calcium/calmodulin-dependent pathways.* Endocr Rev, 2003. **24**(6): p. 719-36.
- 105. Rusnak, F. and P. Mertz, *Calcineurin: form and function*. Physiol Rev, 2000. **80**(4): p. 1483-521.
- 106. Oishi, Y., et al., *Cellular adaptations in soleus muscle during recovery after hindlimb unloading.* Acta Physiol (Oxf), 2008. **192**(3): p. 381-95.
- 107. Di Iorio, A., et al., *Sarcopenia: age-related skeletal muscle changes from determinants to physical disability.* Int J Immunopathol Pharmacol, 2006. **19**(4): p. 703-19.
- 108. Hunter, R.B. and S.C. Kandarian, *Disruption of either the Nfkb1 or the Bcl3 gene inhibits skeletal muscle atrophy.* J Clin Invest, 2004. **114**(10): p. 1504-11.
- 109. Meissner, C., *Mutations of mitochondrial DNA cause or consequence of the ageing process*? Z Gerontol Geriatr, 2007. **40**(5): p. 325-33.
- 110. [Oxidative stress in human diseases]. Srp Arh Celok Lek, 2008. **136 Suppl 2**: p. 158-65.
- 111. Zbreski, M.G., et al., *Effects of cyclosporine-A on rat soleus muscle fiber size and phenotype*. Med Sci Sports Exerc, 2006. **38**(5): p. 833-9.